Wednesday, 05. June 2024

Opening Plenary
18:30 - 20:00 R1
Opening Plenary

Thursday, 06. June 2024

Meet the Experts
07:45 - 08:45 R6

Maximising the value of registries: novel approaches to study design

Gwyneth Davies (London, United Kingdom)
Nicole Hamblett (Seattle, United States)

Meet the Experts
07:45 - 08:45 R6

Sampling and diagnostics of airway infections in the future

Helle Krogh Johansen (Copenhagen, Denmark)
Michael Tunney (Belfast, United Kingdom)

Meet the Experts
07:45 - 08:45 R6

Meet the Experts

Meet the Experts
07:45 - 08:45 R6

Implementing a healthy lifestyle in cystic fibrosis - diet and physical activity

Daina Kalnins (Toronto, Canada)
Gemma Stanford (London, United Kingdom)

Symposium
09:00 - 10:30 R1

***S01* - Symposium 01 - Genetic therapies: getting them into the clinic**

Nicholas Simmonds (London, United Kingdom)
Patrick Harrison (Cork, Ireland)

Gene therapy: an update 09:00 - 09:22

Uta Griesenbach (London, United Kingdom)

mRNA therapy: what's the message so far? 09:22 - 09:44

Margarida Amaral (Lisboa, Portugal)

Making sense out of antisense oligonucleotides 09:44 - 10:06

Batsheva Kerem (Mevaseret, Israel)

Getting genetic therapy into the clinic: the importance of education! 10:06 - 10:30

George Retsch-Bogart (Chapel Hill, United States)

Symposium
09:00 - 10:30 R2

***S02* - Symposium 02 - Innovative solutions: Exploring new therapies for cystic fibrosis pathogens**

Helle Krogh Johansen (Copenhagen, Denmark)
Barbara Kahl (Münster, Germany)

New drug for inhibition of *Pseudomonas aeruginosa* adhesion to the airway epithelia 09:00 - 09:22

Silvia Buroni (Pavia, Italy)

Navigating antibiotic treatment of bacterial pathogens in cystic fibrosis airways during elexacaftor/tezacaftor/ivacaftor therapy 09:22 - 09:44

Michael Parkins (Calgary, Canada)

Bridging the gap: Exploring challenges and opportunities in advancing novel antimicrobial therapeutics for cystic fibrosis 09:44 - 10:06

Freddy Frost (Liverpool, United Kingdom)

Exploring the efficacy of beta-lactam-beta-lactamase inhibitor combinations for the treatment of pulmonary infection caused by *Mycobacterium abscessus* 10:06 - 10:30

Jean-Luc Mainardi (Paris, France)

Symposium
09:00 - 10:30 R3

S03 **- Symposium 03 - Hot topics in lung transplantation**

Lieven Dupont (Leuven, Belgium)

Threshold and indications for lung transplantation - have they changed? 09:00 - 09:22

Peter Barry (Manchester, United Kingdom)

Optimising access - lessons from the French programme 09:22 - 09:44

Antoine Roux (Paris, France)

Is there a role for CFTR modulators in lung transplant recipients? 09:44 - 10:06

Carina M E Hansen (Groningen, Netherlands)

Post-transplant management: is it the time for a change? 10:06 - 10:30

Edward McKone (Dublin 4, Ireland)

Symposium
09:00 - 10:30 R4

S04 **- Symposium 04 - Psychosocial care in the CFTR modulator era: Did expectations align with reality?**

Urszula Borawska-Kowalczyk (Warsaw, Poland)
Maya Kirszenbaum (Paris, France)

How to manage CFTR modulator therapy effects and provide excellent psychosocial care 09:00 - 09:22

Edwina Landau (Petah Tikva, Israel)

Adapting to change - what CFTR modulator therapy means for cystic fibrosis friends and families 09:22 - 09:44

Els van der Heijden (Hekendorp, Netherlands)

What is cystic fibrosis related and what's not? - when to refer outside the cystic fibrosis center 09:44 - 10:06

Stina Järvholm (Gothenburg, Sweden)

New therapy, old problems - empowering people with cystic fibrosis to achieve their dreams and aspirations 10:06 - 10:30

Rachel Massey-Chase (London, United Kingdom)

Symposium
09:00 - 10:30 R5

S05 **- Symposium 05 - Incorporating extensive gene analysis into newborn screening for cystic fibrosis (successfully)**

Kevin Southern (Liverpool, United Kingdom)
Joanne Harrison (Melbourne, Australia)

How should we choose variants to report 09:00 - 09:22

Karen Raraigh (Baltimore, United States)

The Vancouver approach 09:22 - 09:44

Mark Chilvers (Vancouver, Canada)

The Dutch approach 09:44 - 10:06

Karin M. de Winter - de Groot (Utrecht, Netherlands)

The interface with the family 10:06 - 10:30

Jane Chudleigh (London, United Kingdom)

Symposium
11:00 - 12:30 R1

S06 **- Symposium 06 - Gastrointestinal, metabolic and malignant complications in adults with cystic fibrosis**

Monika Mielus (Warsaw, Poland)
Eva Van Braeckel (Ghent, Belgium)

Gastrointestinal complications in adult patients with cystic fibrosis 11:00 - 11:22

Steven D. Freedman (Boston, United States)

Emerging challenges in CF adults with diabetes 11:22 - 11:44

Dimitri Declercq (Ghent, Belgium)

Metabolic syndrome and cardiovascular complications in aging patients with cystic fibrosis 11:44 - 12:06

Daniel Peckham (Leeds, United Kingdom)

Incidence, screening and risk factors of cancer in individuals with cystic fibrosis 12:06 - 12:30

Patrick Maisonneuve (Milan, Italy)

Symposium
11:00 - 12:30 R2

S07 **- Symposium 07 - Airway inflammation - take home messages for clinical care**

Olaf Eickmeier (Frankfurt am Main, Germany)
Gerry McElvaney (Dublin, Ireland)

What drives airway inflammation in cystic fibrosis? 11:00 - 11:22

Robert Gray (Glasgow, United Kingdom)

Cystic fibrosis neutrophils - impact of modulators? 11:22 - 11:44

Veronique Witko-Sarsat (Paris, France)

Can we reliably and repeatedly measure inflammation non-invasively in cystic fibrosis? 11:44 - 12:06

Pursuing anti-inflammatory therapies in cystic fibrosis? 12:06 - 12:30

Malena Cohen-Cymberknoh (Jerusalem, Israel)

Symposium
11:00 - 12:30 R3

S08 **- Symposium 08 - Innovations in action: advancing microbiology methodologies in cystic fibrosis clinical care**

Lucas Hoffman (Seattle, United States)
Silvia Buroni (Pavia, Italy)

Enhanced microbiological sampling efficiency: the role of oropharyngeal swabs, induced sputum and single-use flexible bronchoscopy in adults with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor treatment 11:00 - 11:22

Kevin Deasy (Cork, Ireland)

Decoding bacterial survival strategies: Unraveling the molecular basis of chronic infections through innovative microbiology methodologies 11:22 - 11:44

Joanne Fothergill (Liverpool, United Kingdom)

Uncovering novel mechanisms of antibiotic tolerance using new infection models 11:44 - 12:06

Pablo Laborda (Copenhagen, Denmark)

Exploring the effects of elexacaftor/tezacaftor/ivacaftor therapy on the cystic fibrosis airway microbial metagenome 12:06 - 12:30

Sophia Pallenberg (Hannover, Germany)

Symposium
11:00 - 12:30 R4

***S09* - Symposium 09 - Physiotherapy...Under Pressure**

Lisa Morrison (Glasgow, United Kingdom)
Cecilia Rodriguez Hortal (Stockholm, Sweden)

Positive and negative pressure – finding the balance with adjuncts for airway clearance 11:00 - 11:22

Jamie Wood (New York, United States)

Relieving the pressure – physiotherapy management of sinus disease 11:22 - 11:44

The pressures on – which physiotherapy for an asymptomatic infant with cystic fibrosis? 11:44 - 12:06

Nicky Murray (London, United Kingdom)

Staffing pressure - maintaining acute skills and staff retention in the post-modulator era 12:06 - 12:30

Marlies Wagner (Graz, Austria)

Symposium
11:00 - 12:30 R5

***S10* - Symposium 10 - Nucleic acid therapies – The inside and the outside**

Marianne S. Carlon (Leuven, Belgium)
Uta Griesenbach (London, United Kingdom)

ASO-mediated correction for CFTR splicing and beyond 11:00 - 11:22

Michelle Hastings (Ann Arbor, United States)

Getting from the outside to the inside: airway epithelium disruption to deliver airway genetic therapies efficiently 11:22 - 11:44

David Parsons (North Adelaide, Australia)

Virus-like particles (VesiCas') and base editing 11:44 - 12:06

Giulia Maule (Trento, Italy)

How can we move gene editing from bench to bedside? 12:06 - 12:30

Patrick Harrison (Cork, Ireland)

ePoster Session
14:00 - 15:00 R3

ePoster Session 4 - How to manage lung disease?

EPS4.01 **Impact of 18 months of treatment with Elexacaftor-Tezacaftor-Ivacaftor on clinical outcomes in children aged 6-11 with CF – The RECOVER study** 14:00 - 14:06

Paul McNally (Dublin, Ireland)

EPS4.02 **Exploring Barriers to Treatment Adherence in People with Cystic Fibrosis: Insights from the RECOVER Study at 24 Months** 14:06 - 14:12

Sharon Sutton (Dublin, Ireland)

EPS4.03 **ASOs reducing MUC5AC or MUC5B as a therapeutic approach for CF and other muco-obstructive diseases** 14:12 - 14:18

Efrat Ozeri Galai (Jerusalem, Israel)

EPS4.04 **Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for** 14:18 - 14:24

***Mycobacterium abscessus* treatment (FOR*Ma*T)**

Daniel Hicks (Brisbane, Australia)

EPS4.05 **A multi-center, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis (conneCT CF): Interim analysis** 14:24 - 14:30

Stephanie Thee (Berlin, Germany)

EPS4.06 **Safety of exercise as an airway clearance technique to replace chest physiotherapy in people with cystic fibrosis: preliminary insights from the ExACT-CF trial** 14:30 - 14:36

Zoe Saynor (Portsmouth, United Kingdom)

EPS4.07 **Validation of home spirometry as a CF clinical trial endpoint: Results of the OUTREACH study** 14:36 - 14:42

Margaret Rosenfeld (Seattle, United States)

EPS4.08 **Perception of symptom changes, treatment burden and quality of life are associated with discontinuation of supportive therapy in people with CF treated with elexacaftor/tezacaftor/ivacaftor** 14:42 - 14:48

Simone Ahting (Leipzig, Germany)

EPS4.09 **Lung remodeling by ETI in the adolescent french real world Modul-CF study** 14:48 - 14:54

Isabelle Sermet-Gaudelus (Paris, France)

EPS4.10 **Developing a non-viral gene therapy strategy for treating lung cystic fibrosis disease** 14:54 - 15:00

Bei Qiu (Dublin, Ireland)

ePoster Session
14:00 - 15:00 R4

ePoster Session 5 - New insights in cystic fibrosis liver disease and optimising nutritional care in cystic fibrosis

Gordon Macgregor (Glasgow, United Kingdom)

EPS5.01 **Assessing potential of FIB-4 index and Transient Elastography for use in an adult Cystic Fibrosis population** 14:00 - 14:06

Stephen Armstrong (Belfast, United Kingdom)

EPS5.02 **Alterations of bile acid composition in cystic fibrosis patients as a potential marker of hepato-biliary disease** 14:06 - 14:12

Alexander Kiefer (Regensburg, Germany)

EPS5.03 **CFTR modulators in advanced cystic fibrosis-related liver disease (CFLD): a single centre retrospective analysis** 14:12 - 14:18

Georgeina L Jarman (Cambridge, United Kingdom)

EPS5.04 **A single centre audit of colorectal screening in people with cystic fibrosis** 14:18 - 14:24

Keshini Kulathevanayagam (Cambridge, United Kingdom)

EPS5.05 **Colonoscopy and polyp detection in a large cohort of patients with CF** 14:24 - 14:30

Giulia Spoletini (Leeds, United Kingdom)

EPS5.06 **Is elexacaftor/tezacaftor/ivacaftor therapy associated with lipid profile changes in a Scottish Adult Cystic Fibrosis (CF) centre?** 14:30 - 14:36

Lianne Robb (Edinburgh, United Kingdom)

EPS5.07 **It might not be the enzymes! A single centre experience of investigating bile acid malabsorption** 14:36 - 14:42

Claire Roden (Birmingham, United Kingdom)

EPS5.08 **THE EFFECTS OF NUTRITION THERAPY APPLIED IN PATIENTS** 14:42 - 14:48

WITH CYSTIC FIBROSIS THE QUALITY OF LIFE AND MUSCLE STRENGTH

Damla Kocaman (Istanbul, Turkey)

EPS5.09 **Optimising vitamin D status in cystic fibrosis patients: changes over a ten year period in a United Kingdom adult cystic fibrosis centre** 14:48 - 14:54

Charissa Kettley (Frimley, United Kingdom)

EPS5.10 **Service evaluation of children with cystic fibrosis taking a combined fat soluble vitamin preparation at Alder Hey Children's Hospital** 14:54 - 15:00

Clare J Woodland (Liverpool, United Kingdom)

ePoster Session
14:00 - 15:00 R5

ePoster Session 6 - Broad insights from registries and observational studies

Egil Bakkeheim (Oslo, Norway)
Elpis Hatziagorou (Thessaloniki, Greece)

EPS6.01 **Improved outcome in the adult cystic fibrosis population in Europe from 2012 to 2022: analysis of the European Cystic Fibrosis Society Patient Registry** 14:00 - 14:06

Annalisa Orenti (Milan, Italy)

EPS6.02 **Striking evolution of survival of cystic fibrosis patients in Brittany (western France): an analysis of the last 50 years by birth cohort** 14:06 - 14:12

Julie Derrien (Brest, France)

EPS6.03 **Factors associated with more frequent and severe pulmonary exacerbations in patients with Cystic Fibrosis: data from the ECFS Patient Registry** 14:12 - 14:18

Virginia De Rose (Turin, Italy)

EPS6.04 **Getting ready for the storm: What cardiovascular disease metrics do national cystic fibrosis registries currently collect?** 14:18 - 14:24

Emelia Bature (Liverpool, United Kingdom)

EPS6.05 **Clinical outcomes in concurrent elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treated vs. ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19** 14:24 - 14:30

Christian Merlo (Baltimore, United States)

EPS6.06 **A comprehensive catalog of variation in the *CFTR* gene** 14:30 - 14:36

Karen Raraigh (Baltimore, United States)

EPS6.07 **Costs by circumstances of diagnosis and 10-year cost trajectory in children with cystic fibrosis in France** 14:36 - 14:42

Philippe Reix (Lyon, France)

EPS6.08 **The new frontier of spirometry: The implications of using race-neutral reference equations in the Canadian Cystic Fibrosis Registry** 14:42 - 14:48

Stephanie Y. Cheng (Toronto, Canada)

EPS6.09 **Association of within-individual variability of FEV_1 and BMI with mortality in women with cystic fibrosis: preliminary results from the UK Registry** 14:48 - 14:54

Marco Palma (Cambridge, United Kingdom)

EPS6.10 **Molecular epidemiologic investigation of nontuberculous mycobacteria: identifying healthcare-associated transmission and acquisition** 14:54 - 15:00

Jane E. Gross (Denver, United States)

ePoster Session
14:00 - 15:00 R6

ePoster Sessions 1 - 3

ePoster Session
14:00 - 15:00 R6

ePoster Session 1 - Advances in exercise interventions in the management of cystic fibrosis.

Clare M Reilly (Dublin, Ireland)
Thomas Radtke (Zurich, Switzerland)

EPS1.01 **Predicting ‚optimal' work rate increments for cycle ergometry tests in cystic fibrosis** 14:00 - 14:06

Helge Hebestreit (Würzburg, Germany)

EPS1.02 **High-Intensity Interval Training or Moderate-Intensity Continuous Training: The Effects on Peak Exercise Capacity and Body Composition in Adults with Cystic Fibrosis - a randomized controlled study** 14:06 - 14:12

Wolfgang Gruber (Essen, Germany)

EPS1.03 **Feasibility of obtaining submaximal outcomes in people with advanced cystic fibrosis lung disease undergoing cardiopulmonary exercise testing** 14:12 - 14:18

Don S Urquhart (Edinburgh, United Kingdom)

EPS1.04 **Effect of elexacaftor/tezacaftor/ivacaftor therapy on exercise testing: A three year, real-world, follow up analysis** 14:18 - 14:24

Carlos Pereira Chilima (Exeter, United Kingdom)

EPS1.05 **Increasing motivation and enjoyment of inpatient exercise via the use of technology** 14:24 - 14:30

Nicole Petch (Manchester, United Kingdom)

EPS1.06 **The validity and reliability of the Turkish version of the AWESCORE test** 14:30 - 14:36

Ozge Kenis-Coskun (İstanbul, Turkey)

EPS1.07 **Has participation in physical activity in adults with cystic fibrosis changed over the last 20 years?** 14:36 - 14:42

Rebecca J McVean (Manchester, United Kingdom)

EPS1.08 **Feasibility and tolerance of a high intensity interval training program in adults with cystic fibrosis** 14:42 - 14:48

Sophie Ramel (Roscoff, France)

EPS1.09 **Does Elexacaftor/Tezacaftor/Ivacaftor influence carbon dioxide retention at peak exercise?** 14:48 - 14:54

Ian Waller (Wythenshawe, United Kingdom)

EPS1.10 **Physical Activity and Health Outcomes in Children with Cystic Fibrosis** 14:54 - 15:00

Kieren James Lock (Cambridge, United Kingdom)

ePoster Session
14:00 - 15:00 R6

ePoster Session 3 - Managing cystic fibrosis pathogens

Pavel Drevinek (Prague, Czech Republic)

EPS3.01 **A comparison of routine cough swabs vs a novel sputum sampling technique in a paediatric population** 14:00 - 14:06

Tom Meredith (Southampton, United Kingdom)

EPS3.02 **'Thinking outside the (sputum) box'** 14:06 - 14:12

Simone Hadjisymeou Andreou (London, United Kingdom)

EPS3.03 **Investigations of Host-Microbe interactions in Air-Liquid-Interphase lung epithelial cell cultures by dual-species meta-transcriptomics** 14:12 - 14:18

Claudia A Colque (Copenhagen, Denmark)

EPS3.04 **Reversal of levofloxacin resistance in cystic fibrosis-associated *Pseudomonas aeruginosa* through dual inhibition of efflux pumps and DNA topoisomerases** 14:18 - 14:24

Callum Matthew Sloan (Belfast, United Kingdom)

EPS3.05 **Welsh housing quality and fungal respiratory growths from adults with Cystic Fibrosis** 14:24 - 14:30

Amelia Collins (Cardiff, United Kingdom)

EPS3.06 **Diagnostic target product profiles for managing infections and exacerbations in cystic fibrosis** 14:30 - 14:36

Rebecca Holmes (London, United Kingdom)

EPS3.07 **Overproduction of cyclic-di-AMP in thymidine dependent-small colony variant *Staphylococcus aureus* may contribute to hyperinflammation in people with CF** 14:36 - 14:42

Daniel J. Wolter (Seattle, United States)

EPS3.08 **Evolution through chromosomal adaptation and coexistence of selected clones: how *Pseudomonas aeruginosa* endures in cystic fibrosis airways and affects prognosis** 14:42 - 14:48

Martina Rossitto (Rome, Italy)

EPS3.09 **The value of serology in diagnostics of *Pseudomonas aeruginosa* infections in people with cystic fibrosis** 14:48 - 14:54

Pavel Drevinek (Prague, Czech Republic)

EPS3.10 **Phage Therapy for Antibiotic-Resistant Pseudomonas aeruginosa: Overcoming Manufacturing Barriers in the UK – a step towards clinical trials for people with Cystic Fibrosis in the UK** 14:54 - 15:00

Libby Duignan (Liverpool, United Kingdom)

ePoster Session
14:00 - 15:00 R6

ePoster Session 2 - Managing complexity of cystic fibrosis challenges

Trudy Havermans (Leuven, Belgium)

EPS2.01 **Recruitment via social media results in systematic differences in responses to survey-based research in CF; but is this always a bad thing?** 14:00 - 14:06

Rebecca Dobra (London, United Kingdom)

EPS2.02 **Development and implementation of a fertility preservation telehealth counseling intervention for males with cystic fibrosis** 14:06 - 14:12

Sigrid Ladores (Birmingham, United States)

EPS2.03 **Sexual and reproductive health experiences and care utilization of males with cystic fibrosis compared to the general United States population** 14:12 - 14:18

Traci Kazmerski (Pittsburgh, United States)

EPS2.04 **Sexual dysfunction in cystic fibrosis** 14:18 - 14:24

Sophie Ramel (Roscoff, France)

EPS2.05 **Memory issues in Cystic Fibrosis- Are we missing this and do we forget to ask?** 14:24 - 14:30

Arouba Imtiaz (Cardiff, United Kingdom)

EPS2.06 **Audit of the incidence of Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in the Paediatric** 14:30 - 14:36

Cystic Fibrosis Service at Addenbrookes Hospital in Cambridge, UK

Amy Shayle (Cambridge, United Kingdom)

EPS2.07 **The prevalence, associated clinical symptoms & measurement of pain in cystic fibrosis** 14:36 - 14:42

Anastasia Ward (Gold Coast, Australia)

EPS2.08 **Anxiety and spirometry: prevalence, patient experience, and how providers can help** 14:42 - 14:48

Heather Bruschwein (Charlottesville, United States)

EPS2.09 **Perspectives on implementing eHealth CF-CBT in the Netherlands: The first digital mental health intervention for depression/anxiety in adults with cystic fibrosis** 14:48 - 14:54

Marieke Verkleij (Amsterdam, Netherlands)

EPS2.10 **An exploration of staff wellbeing in Cystic Fibrosis (CF) in Ireland: a national survey** 14:54 - 15:00

Helen Gibbons (Tallaght, Ireland)

Poster Viewing
14:00 - 15:00

Poster Viewing 1

P001 **Evaluation of the relationship between quantitative levels of immune-reactive trypsinogen & sweat chloride levels, genetic mutations, and pancreatic involvement in cystic fibrosis patients** 14:00 - 14:00

Fazılcan Zirek (Ankara, Turkey)

P002 **Charting the Course: A 10-Year Overview of Cystic Fibrosis Newborn Screening in Portugal** 14:00 - 14:00

Bernardo Camacho (Funchal, Madeira, Portugal)

P003 **Outcome of Children with IRT/IRT Newborn Screening Positivity: An 8-Year Follow-Up of Tertiary Centre** 14:00 - 14:00

Tugce Celtik (Ankara, Turkey)

P004 **Newborn screening for Cystic Fibrosis (CF-NBS) in Wallonia-Brussels Federation (Belgium): report of first evaluation after 3 years** 14:00 - 14:00

Matthieu Thimmesch (Liège, Belgium)

P005 **Seven-year Follow-up of Patients with Cystic Fibrosis After Newborn Screening Program** 14:00 - 14:00

Handan Kekeç (Ankara, Turkey)

P006 **False negative newborn screen and absent clinical features of cystic fibrosis after *in utero* modulator exposure for an infant with two cystic fibrosis causing mutations** 14:00 - 14:00

Chris Fortner (Syracuse, United States)

P007 **Long term clinical follow up of patients with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome(CRMS/CFSPID)** 14:00 - 14:00

Didem Alboğa (Ankara, Turkey)

P008 **Scoping review of factors that influence cystic fibrosis (CF) transmembrane conductance regulator related metabolic syndrome/CF Screen positive, inconclusive diagnosis outcomes and management** 14:00 - 14:00

Jane Chudleigh (London, United Kingdom)

P009 **CF, CFSPID, CF-RD, diagnostic dilemmas after CF-newbornscreening and sweat testing** 14:00 - 14:00

Jutta Hammermann (Dresden, Germany)

P010 **Cystic Fibrosis Screening Challenges In Georgia:** 14:00 - 14:00
Nino Vardosanidze (Tbilisi, Georgia)

P011 **Parental experiences of CF diagnosis through newborn screening in the US: a survey study** 14:00 - 14:00
Susanna McColley (Chicago, United States)

P012 **Advancing precision in cystic fibrosis registries: identification and classification of patients with unclear diagnosis in the Norwegian cystic fibrosis patient registry** 14:00 - 14:00
Anita C. Senstad Wathne (Oslo, Norway)

P013 **The New Sight at Cystic Fibrosis Patient Screening** 14:00 - 14:00
Merve Nur Tekin (Ankara, Turkey)

P014 **Improvement, but persistent disparities, exist in age at first event for US infants with CF** 14:00 - 14:00
Stacey Martiniano (Aurora, United States)

P015 **Innovating CF diagnosis in resource-limited settings: The efficacy of salivary chloride detection strips** 14:00 - 14:00
Supriya Suresh Shinde (Southampton, United Kingdom)

P016 **Ethical implications in patient stratification through standardisation of the image-based sweat test for cystic fibrosis in clinical routine** 14:00 - 14:00
Lea Wilken (Hamburg, Germany)

P017 **Sweat test: different clinical questions require different lab reports** 14:00 - 14:00
Natalia Cirilli (Ancona, Italy)

P018 **Meconium Ileus - managing Cystic Fibrosis screening and nutritional management** 14:00 - 14:00
Jacqueline Lowdon (Leeds, United Kingdom)

P019 **Chest Computed Tomography Imaging Practices of People with Cystic Fibrosis: Insights from Radiologists, Radiographers, and Pulmonologists** 14:00 - 14:00
Michael G Waldron (Cork, Ireland)

P020 **Ultra-low dose chest computed tomography versus chest radiography in paediatric cystic fibrosis: a prospective study** 14:00 - 14:00
Michael G Waldron (Cork, Ireland)

P021 **Non-classical pulmonary exacerbation in a patient with Cystic fibrosis: Case report** 14:00 - 14:00
Mohamad Hadhud (Jerusalem, Israel)

P022 **Reproductive examination in differential diagnosis of Cystic Fibrosis and CFTR-related disorders in male patients** 14:00 - 14:00
Vyacheslav Chernykh (Moscow, Russian Federation)

P023 **Reproductive issues and diagnosis of cystic fibrosis** 14:00 - 14:00
Guergana Petrova (Sofia, Bulgaria)

P481 **MRI as a follow-up to lung CT to evaluate suspicious lung nodules using a modified Lung-RADS scoring system in patients with cystic fibrosis** 14:00 - 14:00
Marcus Mall (Berlin, Germany)

P024 **Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis** 14:00 - 14:00
Elena Kondratyeva (Moscow, Russian Federation)

P025 **The haves and the have nots: characterising the CFTR protein modulator ineligible cohort in a large paediatric cystic fibrosis (CF)** 14:00 - 14:00

centre

Benjamin Davies (Birmingham, United Kingdom)

P026 **Non eligibility for CFTR modulator therapies: who is forgotten?** 14:00 - 14:00

Edna Lúcia Souza (Salvador, Brazil)

P027 **This study presents a comprehensive genetic and clinical profiling of patients with Cystic Fibrosis ineligible for CFTR modulator therapy, offering insights from a diverse patient cohort** 14:00 - 14:00

Ceren Ayça Yıldız (Istanbul, Turkey)

P028 **This study assesses Cystic Fibrosis regulatory modulators through a comprehensive retrospective analysis on patient subgroups and clinical outcomes** 14:00 - 14:00

Ceren Ayça Yıldız (Istanbul, Turkey)

P029 **Complex *CFTR* allele F508del-L467F in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy: a retrospective analysis in three Czech cases who partially respond to ETI** 14:00 - 14:00

Marcela Kreslová (Pilsen, Czech Republic)

P030 **Clinical and genetic characteristics of carriers of complex alleles of the *CFTR* gene** 14:00 - 14:00

Yuliya Melyanovskaya (Moscow, Russian Federation)

P031 **Determining the genotypic and phenotypic characteristics of patients in the Turkish National Cystic Fibrosis Registry System** 14:00 - 14:00

Nilgün Kula (Ankara, Turkey)

P032 **CFTR gene variants in the group of adult Cystic Fibrosis patients in Kazakhstan** 14:00 - 14:00

Elena Amelina (Moscow, Russian Federation)

P033 **Impact of genetics on body mass index in patients with Cystic fibrosis** 14:00 - 14:00

Elena Gjinovska-Tasevska (Skopje)

P034 **Genetic polymorphisms of ACE gene (rs4646994), PPARGC1A gene (rs8192678) in children with Cystic fibrosis in the Russian Federation”** 14:00 - 14:00

Tatyana Maksimycheva (Moscow, Russian Federation)

P035 **Establishing GIWU-CF cohort for studies of genetic factors influencing CF susceptibility** 14:00 - 14:00

Oksana Tyshchenko (Lviv, Ukraine)

P036 **Targeting ATP12A proton pump provides new therapeutic opportunities for cystic fibrosis** 14:00 - 14:00

Giulia Gorrieri (Genoa, Italy)

P037 **A platform for biomarkers evaluation, pathophysiology studies, and therapeutic development based on patient-derived cells collected by nasal brushing** 14:00 - 14:00

Giulia Gorrieri (Genoa, Italy)

P038 **Exploring gene and protein expression patterns associated with nonsense mutations as novel therapeutic targets** 14:00 - 14:00

Carlos M Farinha (Lisboa, Portugal)

P039 **Lactonase benefits to counteract the impacts of *Pseudomonas aeruginosa* virulence on the early phases of airway epithelial wound repair in cystic fibrosis** 14:00 - 14:00

Sarah Moustadraf (Montreal, Canada)

P040 **Theranostics for People with Cystic Fibrosis and Rare CFTR Variants** 14:00 - 14:00

Margarida Amaral (Lisboa, Portugal)

P041 **The difference in lung clearance index using multiple breath Helium and Sulphur Hexafluoride washout** 14:00 - 14:00

Mollie Elizabeth Riley (London, United Kingdom)

P042 **Partial Rescue of p.Phe08del-CFTR Trafficking and Stability Defects by Dual and Triple Corrector Combinations** 14:00 - 14:00

Miquéias Lopes-Pacheco (Lisbon, Portugal)

P043 **The oxygen pulse response during cardiopulmonary exercise testing in our paediatric cystic fibrosis population** 14:00 - 14:00

Colleen Carden (Glasgow, United Kingdom)

P044 **Noisy breathing during exercise in a Cystic Fibrosis patient – What's the cause?** 14:00 - 14:00

Colleen Carden (Glasgow, United Kingdom)

P045 **Lenticlair™ 1: A Phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators** 14:00 - 14:00

Eric Alton (London, United Kingdom)

P046 **Lenticlair™-ON: An extension trial examining long-term safety and efficacy outcomes associated with an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF** 14:00 - 14:00

Jane Davies (London, United Kingdom)

P047 **Patient perspectives on cystic fibrosis gene therapy clinical trials** 14:00 - 14:00

Maggie Patricia McIlwaine (Toronto, Canada)

P048 **Renal effects of triple CFTR modulator therapy** 14:00 - 14:00

Pierre Gabai (Villeurbane, France)

P049 **Calcium Activated Chloride Channel Activators – A Potential Therapeutic Strategy for All Cystic Fibrosis Patients?** 14:00 - 14:00

Jinghuai Tan (St Andrews, United Kingdom)

P050 **Investigating the therapeutic effects of K+ channel modulators in cystic fibrosis epithelia** 14:00 - 14:00

Omar Hamed (London, United Kingdom)

P051 **Proteomics unveils unique host and microbial signatures linked to key clinical trial outcomes in cystic fibrosis trials** 14:00 - 14:00

Sian Pottenger (Liverpool, United Kingdom)

P052 **Real-life experience with a generic formulation of Elexacaftor/Tezacaftor/ Ivacaftor in patients with Cystic Fibrosis and responsive *CFTR* variants with previous modulators therapy** 14:00 - 14:00

Silvina Zaragoza (Buenos Aires, Argentina)

P053 **Real-life experience with a generic formulation of Elexacaftor/Tezacaftor/ Ivacaftor in patients with Cystic Fibrosis with responsive CFTR variants without previous modulators therapy** 14:00 - 14:00

Alejandro Teper (Buenos Aires, Argentina)

P054 **Effect of a generic formulation of Elexacaftor/Tezacaftor/Ivacaftor on sputum cultures in Cystic Fibrosis patients without previous *CFTR* Modulator Therapy** 14:00 - 14:00

Gabriela Manonelles (Ciudad de Buenos Aires, Argentina)

P055 **REAL-LIFE EXPERIENCE WITH A GENERIC FORMULATION OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN CHILDREN WITH CYSTIC FIBROSIS** 14:00 - 14:00

María Macarena Oneglia (Buenos Aires, Argentina)

P056	**Elexacaftor/Tezacaftor/Ivacaftor and breastfeeding: 3 cases of liver enzymes abnormalities in breastfeed children**	14:00 - 14:00
Sandrine Bergeron (Lille, France)		
P057	**Measuring Adherence to Chronic Therapies over the First Year of Treatment with Elexacaftor/Tezacaftor/Ivacaftor (ETI) in People with Cystic Fibrosis (CF) aged 6-11 years – the RECOVER study**	14:00 - 14:00
Sharon Sutton (Dublin, Ireland)		
P058	**Long term indications and clinical outcomes in sustained dose reduction strategies for elexacaftor/tezacaftor/ivacaftor (ETI): a case series**	14:00 - 14:00
Noreen Tangney (Cork, Ireland)		
P059	**Associations between olfactory dysfunction, eating-related quality of life, chronic rhinosinusitis, and highly effective modulator therapy in people with cystic fibrosis**	14:00 - 14:00
Christine Liu (Los Angeles, United States)		
P060	**Impact of Elexacaftor/Tezacaftor/Ivacaftor on Eradication of Nontuberculous Mycobacteria in Children with Cystic Fibrosis: Case Series from Czech Republic**	14:00 - 14:00
Marcela Kreslová (Pilsen, Czech Republic)		
P061	**Effect of elexacaftor/tezacaftor/ivacaftor on inflammatory parameters and bacterial respiratory cultures in children and adolescents with cystic fibrosis: a retrospective, dual-center cohort study**	14:00 - 14:00
Angela Pepe (Potenza, Italy)		
P063	**ELX/TEZ/IVA has beneficial effects on clinical outcomes and quality of life in people with cystic fibrosis in the real-world TRAJECTORY study**	14:00 - 14:00
Amparo Solé (Valencia, Spain)		
P064	**IMPROVED QUALITY OF LIFE IN CYSTIC FIBROSIS PATIENTS OBSERVED UP TO 36 MONTHS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR TREATMENT**	14:00 - 14:00
Francesca Buniotto (Verona, Italy)		
P065	**Use of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with rare mutations**	14:00 - 14:00
Valentina Fainardi (Parma, Italy)		
P066	**Treatment effects of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for 3849+10kbC->T**	14:00 - 14:00
Moshe Heching (Petach Tikva, Israel)		
P067	**Low efficiency of elexacaftor/tezacaftor/ivacaftor (ETI) in patients heterozygous W1282R and class I mutations**	14:00 - 14:00
Elena Zhekaite (Moscow, Russian Federation)		
P068	**EFFECTIVENESS OF ETI IN PEOPLE WITH CYSTIC FIBROSIS AND NO F508DEL CFTR VARIANT: A MULTICENTER STUDY IN GREECE**	14:00 - 14:00
Aikaterini Manika (Thessaloniki, Greece)		
P069	**Experience in the use of Elexacaftor/Tezacaftor/Ivacaftor in cystic fibrosis patients of the Chechen ethnic group in the Russian Federation**	14:00 - 14:00
Yulia Gorinova (Moscow, Russian Federation)		
P070	**The proof of the pudding is in the eating: real-life intra- and extrapulmonary impact of elexacaftor/tezacaftor/ivacaftor**	14:00 - 14:00
Stefanie Vincken (Jette, Belgium)		
P071	**Elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and**	14:00 - 14:00

	***Phe508del*-gating or *Phe508del*-residual function genotypes: an Italian real-world experience**	
Angela Pepe (Potenza, Italy)		
P072	**Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a CF Center**	14:00 - 14:00
Marco Cipolli (Verona, Italy)		
P073	**Real-world use of the Highly Effective Modulator Therapy elexacaftor/tezacaftor/ivacaftor: A retrospective single-center observational study**	14:00 - 14:00
Jasmijn Koopman (Utrecht, Netherlands)		
P074	**Long-term safety and effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI): A 48-week observational study in a single Reference Centre**	14:00 - 14:00
Elsa Fragoso (Lisbon, Portugal)		
P075	**Long-term effectiveness and safety of Elexacaftor/Tezacaftor/Ivacaftor in daily practice of cystic fibrosis center in the Republic of Tatarstan**	14:00 - 14:00
Yulia Gorinova (Moscow, Russian Federation)		
P076	**The effectiveness of triple modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary function in cystic fibrosis patients with advanced lung disease**	14:00 - 14:00
Elena Krsteska (Skopje, North Macedonia)		
P077	**Adverse effects of CFTR modulator use in patients aged 2-18 with cystic fibrosis**	14:00 - 14:00
Irina Fatkhullina (Moscow, Russian Federation)		
P078	**Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation**	14:00 - 14:00
Niamh O'Flaherty (Dublin, Ireland)		
P079	**Elexacaftor/tezacaftor/ivacaftor: a first case of severe rash in Croatia and our approach to desensitization**	14:00 - 14:00
Tea Vukić (Zagreb, Croatia)		
P080	**Impact of elexacaftor/tezacaftor/ivacaftor on sweat test values in cystic fibrosis patients in North Macedonia**	14:00 - 14:00
Elena Krsteska (Skopje, North Macedonia)		
P081	Comparative analysis of CFTR modulators: unravelling the impact on radiological and clinical outcomes	14:00 - 14:00
Isabella Comello (Treviso, Italy)		
P082	**Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform**	14:00 - 14:00
Galit Livnat (Haifa, Israel)		
P083	**Sweat chloride concentrations in patients before and during treatment with CFTR modulators (mCFTR)**	14:00 - 14:00
Lukasz Wozniacki (Warsaw, Poland)		
P084	**Are Cystic Fibrosis teams using sweat chloride as a clinical biomarker when prescribing CFTR modulators?**	14:00 - 14:00
Paddy McCrossan (Glasgow, United Kingdom)		
P085	**One-year of highly effective modulator therapy in children and young adults with cystic fibrosis: a single-centre experience**	14:00 - 14:00
Lucia Ronco (Turin, Italy)		
P086	**Evaluation of the efficiency of targeted therapy in children with CF in Moscow, Russian Federation**	14:00 - 14:00

Olga Vysokolova (Moscow, Russian Federation)

P087 **Experiences and opinions of cystic fibrosis patients and their families about their inability to access modulator treatments in Türkiye: A qualitative study** 14:00 - 14:00

Ozge Kenis-Coskun (İstanbul, Turkey)

P088 **Implementation of a multiple breath nitrogen washout certification and device loan programme to support clinical trial readiness** 14:00 - 14:00

Clare Saunders (London, United Kingdom)

P089 **FORMaT: Finding the Optimal Regimen for *Mycobacterium abscessus* Treatment. A randomised, multi-arm, adaptive platform trial** 14:00 - 14:00

Cecilia Adetayo (Nottingham, United Kingdom)

P090 **Mission (almost) impossible: setting up a complex investigator led international adaptive platform trial – Finding the Optimal Regimen for *Mycobacterium abscessus* Treatment (FOR*Ma*T)** 14:00 - 14:00

Tiffany Jong (Brisbane, Australia)

P091 **Dual Inhaled Antibiotics for Treatment of Pulmonary Exacerbations in Cystic Fibrosis – a Real Life Pilot Study** 14:00 - 14:00

Moshe Heching (Petach Tikva, Israel)

P092 **Efficacy and tolerability of dornase alfa biosimilar in children and adults with cystic fibrosis** 14:00 - 14:00

Vera Shadrina (Perm, Russian Federation)

P093 **Impact of airway blockage and ventilation heterogeneity in CF on deposition of inhaled drug particles** 14:00 - 14:00

James D Shemilt (Manchester, United Kingdom)

P094 **Feasibility and satisfaction of a follow-up alternating face-to-face consultations and teleconsultations for patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)** 14:00 - 14:00

Thomas Vidal (Pierre-Bénite, France)

P095 **Design and development of smartphone-based digital biomarkers to support recent changes in cystic fibrosis care** 14:00 - 14:00

Christophe Marguet (Rouen, France)

P096 **Qualitative interviews confirming the faithful electronic migration of the Preschool Pictorial Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Parent Preschool CFQ-R** 14:00 - 14:00

Alexandra Quittner (Hollywood, United States)

P097 **E-learning within the European Cystic Fibrosis Society - A multidisciplinary cross sectional survey** 14:00 - 14:00

Chris Smith (Brighton, United Kingdom)

P098 **National, transparent inclusion process provided maximal opportunities for Dutch people with CF to participate in clinical trial** 14:00 - 14:00

Ilonka Paalvast (Den Haag, Netherlands)

P099 **The London CTAP network standard operating procedure for averting medications prohibited during clinical trials in cystic fibrosis** 14:00 - 14:00

Melanie Le Sayec (London, United Kingdom)

P100 **Quality Improvement in Team Collaboration for Cystic Fibrosis Research: Bridging Communication Between the Research Delivery & Facilitator Teams** 14:00 - 14:00

Yasmine Needham (London, United Kingdom)

P101	**To study the effect of CF Modulator KAFTRIO on quantitative reduction of sweat chloride in a cohort of children with cystic fibrosis in shared care centre**	14:00 - 14:00
Rajesh Srikantaiah (Coventry, United Kingdom)		
P143	**Automated computed tomography airway measures of effects of CFTR modulator therapy**	14:00 - 14:00
Gabrielle Baxter (London, United Kingdom)		
P144	**The diagnostic value of chest X-rays for the evaluation of increased symptoms in adults with Cystic Fibrosis: time to move on?**	14:00 - 14:00
Eilish Smyth (Leicester, United Kingdom)		
P145	**Long term effects of the high effective modulator therapy on lung structure and function in children and adolescents with cystic fibrosis**	14:00 - 14:00
Irena Wojsyk - Banaszak (Poznań, Poland)		
P146	**Lung structural changes and cardiorespiratory functional parameters in adult patients with cystic fibrosis**	14:00 - 14:00
Alexander Chernyak (Moscow, Russian Federation)		
P147	**Multivariate analysis of change in FEV1 in cystic fibrosis (CF) patients in two different age groups over three years**	14:00 - 14:00
Oksana G. Zonenko (Moscow, Russian Federation)		
P148	**Effectiveness of elaxacaftor/tezacaftor/ivacaftor (ETI) on oxidative stress in patients with cystic fibrosis**	14:00 - 14:00
Giuseppe Fabio Parisi (Catania, Italy)		
P149	**Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment on clinical outcomes in a single centre cohort of paediatric patients with Cystic Fibrosis. *Royal Children's Hospital Melbourne, Australia.***	14:00 - 14:00
Chloe Crainie (Aberdeen, United Kingdom)		
P150	**Impact of Adverse Effects on CFTR Modulator Dosing in People with Cystic Fibrosis (PwCF)**	14:00 - 14:00
David Young (Salt Lake City, United States)		
P151	**Added Benefit of Triple Therapy for Cystic Fibrosis Patients with Phe508del–Gating Genotype: A Real-world Prospective Study**	14:00 - 14:00
Hisham Ibrahim Saeed Ibrahim (Cork, Ireland)		
P152	**Real-life impact of CFTR modulator therapy on respiratory system in children with cystic fibrosis**	14:00 - 14:00
Katarzyna Walicka-Serzysko (Warsaw)		
P153	**Effects of modulator therapy in cystic fibrosis Portuguese pediatric patients – a national retrospective study**	14:00 - 14:00
Susana Castanhinha (Lisboa, Portugal)		
P154	**Fertility and Pregnancy Outcomes in Cystic Fibrosis Patients on CFTR Modulators Era: Insights from Portugal**	14:00 - 14:00
Fátima Barbosa (Coimbra, Portugal)		
P155	**Presentation and recovery from pulmonary exacerbation in those with and without CFTR modulators**	14:00 - 14:00
Evelyn Looi (Manchester, United Kingdom)		
P156	**Effects of Lumacaftor/Ivacaftor in CF children 2-6 years old: a case series**	14:00 - 14:00
Valentina Fainardi (Parma, Italy)		
P157	**Cystic fibrosis transmembrane regulator modulator therapy and acne in patients with cystic fibrosis**	14:00 - 14:00

Guergana Petrova (Sofia, Bulgaria)

P158 **Necrotizing pneumonia and cystic fibrosis - now and then** 14:00 - 14:00

Guergana Petrova (Sofia, Bulgaria)

P159 **Safety, clinical effectiveness, and changes in systemic cytokine profiles in solid organ transplant recipients post 6 months of Elexacaftor/Tezacaftor/Ivacaftor therapy. A case series** 14:00 - 14:00

Emily M O Reilly (Cork, Ireland)

P160 **Evaluating the process of initiating elexacaftor/tezacaftor/ivacaftor in lung transplant recipients and its effects on immunosuppression medication** 14:00 - 14:00

Lowri Hannah Thomas (Cardiff, United Kingdom)

P161 **A comparison of spirometry quality between home testing and hospital testing and in adults with Cystic Fibrosis** 14:00 - 14:00

David Green (Liverpool, United Kingdom)

P162 **Conditional change score as a marker for improvement in lung function in the era of CFTR modulators - a real-life study** 14:00 - 14:00

Ana Margarida Silva (Lisbon, Portugal)

P163 **Reliability, reproducibility, and responsiveness of home spirometry in regular cystic fibrosis care** 14:00 - 14:00

Marc C. Oppelaar (Nijmegen, Netherlands)

P164 **Utility of $LCI_{2.5}$ as an outcome measure for people with cystic fibrosis of all ages – Experience from a pilot feasibility trial spanning adult and paediatric care** 14:00 - 14:00

Debbie Miller (Edinburgh, United Kingdom)

P165 **Lung Clearance Index in adult patients with atypical Cystic Fibrosis and normal FEV_1** 14:00 - 14:00

Almudena Felipe Montiel (Barcelona, Spain)

P166 **Utility of lung clearance index ($LCI_{2.5}$) as an outcome measure in cystic fibrosis clinical trials – perspectives of people with cystic fibrosis and $LCI_{2.5}$ operators** 14:00 - 14:00

Ellyse Kilarksi (Edinburgh, United Kingdom)

P167 **The relationship of lung clearance index with radiological and microbiological findings and spirometric parameters in children with cystic fibrosis with normal FEV_1 values** 14:00 - 14:00

Meltem Yıldız Kayaoğlu (Ankara, Turkey)

P168 **Clinical utility and application of Lung Clearance Index (LCI) for cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) and adults with an unclear CF diagnosis** 14:00 - 14:00

Mary Abkir (London, United Kingdom)

P169 **Lung Clearance Index as an alternative respiratory outcome in Elexacaftor-Tezacaftor-Ivacaftor treated patients without clinically important improvement in forced expiratory volume in one second** 14:00 - 14:00

Gianfranco Alicandro (Milan, Italy)

P170 **Variability of intra-breath oscillometry in children with Cystic Fibrosis** 14:00 - 14:00

Tamara Blake (South Brisbane, Australia)

P171 **Feasibility of home-based oscillometry monitoring in paediatric Cystic Fibrosis** 14:00 - 14:00

Tamara Blake (South Brisbane, Australia)

P172 **Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis** 14:00 - 14:00

Mohamed Gomaa (Sherbrooke, Canada)

P173 **An alternative method for lung function evaluation applying Impulse Oscillometry. A case study in children with Cystic Fibrosis** 14:00 - 14:00

Virginia D Alessandro (La Plata, Argentina)

P174 **Effect of inhaled salbutamol on breath signatures in adult patients with cystic fibrosis using real-time proton mass spectrometry** 14:00 - 14:00

Malika Mustafina (Moscow, Russian Federation)

P175 **Volatile organic compound breath signatures in mild and severe phenotypes of cystic fibrosis by real-time proton mass spectrometry** 14:00 - 14:00

Malika Mustafina (Moscow, Russian Federation)

P176 **Retrospective evaluation of effect of modulator elexacafor/tezacaftor/ivacaftor (ETI) on immunological markers of Allergic Bronchopulmonary Aspergillosis (ABPA) and clinical relevance** 14:00 - 14:00

Rebecca Thomas (York, United Kingdom)

P177 **Impact of Elexacafor/Ivacaftor/Tezacaftor therapy on *Aspergillus fumigatus* sensitization in Cystic Fibrosis patients** 14:00 - 14:00

Chiara Lanfranchi (Milan, Italy)

P178 **Case report of acute lymphoblastic leukaemia and aspergillus lung infection in a child with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor** 14:00 - 14:00

Nao Doylend (Leeds, United Kingdom)

P179 **Challenges of treating Tuberculosis in child on Cystic Fibrosis Modulator therapy** 14:00 - 14:00

Jill Watkinson (Manchester, United Kingdom)

P180 **Dynamics of IgG antibodies against Pseudomonas aeruginosa in pwCF on ETI treatment – preliminary data** 14:00 - 14:00

Miriam Mala (Brno, Czech Republic)

P181 **Pseudomonas Rates Post Cystic fibrosis transmembrane conductance regulator (CFTR) Modulators and Outcomes in Those Stopping Inhaled Antibiotics** 14:00 - 14:00

Shirin Hamid (Wolverhampton, United Kingdom)

P182 **Non-tuberculous mycobacteria: a factsheet for people with cystic fibrosis and their families** 14:00 - 14:00

Jade Ashton (London, United Kingdom)

P183 **Elucidating the intrinsic defects in cystic fibrosis neutrophils** 14:00 - 14:00

Ana Lúcia Da Silva Cunha (Leuven, Belgium)

P184 **Is there a connection between cystic fibrosis and psoriasis?** 14:00 - 14:00

Guergana Petrova (Sofia, Bulgaria)

P185 **Idiopathic pulmonary fibrosis in a patient with Cystic fibrosis** 14:00 - 14:00

Johannes Till Othmer (Berlin, Germany)

P186 **Immunization against Influenza and SARS-CoV-2 in patients with cystic fibrosis** 14:00 - 14:00

Ivana Arnaudova Danevska (Skopje)

P187 **Four years of experience with SARS–CoV-2 infections in patients with Cystic Fibrosis in a German CF centre** 14:00 - 14:00

Michael Lorenz (Jena, Germany)

P188 **Virtual CF clinic - a pioneering pilot project** 14:00 - 14:00

Carsten Schwarz (Potsdam, Germany)

P189 **The effect of infective exacerbations on sleep quality in adult patients with Cystic Fibrosis** 14:00 - 14:00

Eleni Papadaki (Thessaloniki, Greece)

P190 **Comparison of Children with Cystic Fibrosis Presented with Pseudobartter Syndrome Regarding Sweat Chloride Levels** 14:00 - 14:00

Burcu Capraz Yavuz (Ankara, Turkey)

P191 **Clinical outcomes in the years before and after young people with cystic fibrosis transition from paediatric to adult care** 14:00 - 14:00

Mohammed Ridwan Rahman (Stoke-on-Trent, United Kingdom)

P192 **Neutrophil-to-lymphocyte ratio: a potential biomarker for pulmonary exacerbations in children with cystic fibrosis** 14:00 - 14:00

Nicole Wing Hei Tung (London, United Kingdom)

P193 **Cytokine values in nasal lavage samples of patients with cystic fibrosis indicate a primary mucosal immune response in patients with mild lung disease** 14:00 - 14:00

Teresa Fuchs (London, United Kingdom)

P194 **Impact of chronic *Pseudomonas aeruginosa* infection on the inflammatory response during virus-associated exacerbations of cystic fibrosis lung disease** 14:00 - 14:00

Carla Bellinghausen (Frankfurt, Germany)

P195 **Vaping and cystic fibrosis: current perceptions and future directions** 14:00 - 14:00

Ross Langley (United Kingdom)

P196 **Establishment of a co-culture air-liquid-interphase lung model utilizing human macrophages** 14:00 - 14:00

Alexander Frederick Melanson (Copenhagen, Denmark)

Workshop
15:00 - 16:30 R1

WS01 - Measuring impact in cystic fibrosis treatment

Mirjam Stahl (Berlin, Germany)
Annelies M. Zwitserloot (Groningen, Netherlands)

WS01.01 **Clinical validation of automated vs manual PRAGMA-CF CT score in children with CF** 15:00 - 15:15

Pranali Raut (Rotterdam, Netherlands)

WS01.02 **Dynamic chest radiography in people with cystic fibrosis – a new method of measuring simple lung function** 15:15 - 15:30

David Green (Liverpool, United Kingdom)

WS01.03 **Effects of Elexacaftor/Tezacaftor/Ivacaftor in Lung Transplant Recipients with Cystic Fibrosis: The Dutch national KOALA Study** 15:30 - 15:45

Johanna Petronella van Gemert (Groningen, Netherlands)

WS01.04 **Real-world outcomes in people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) with up to three years of follow-up** 15:45 - 16:00

Julie K. Bower (Boston, United States)

WS01.05 **Long-term real-world outcomes of CFTR modulation with Ivacaftor in adult cystic fibrosis patients with the G551D mutation; 8 years single center real-world study** 16:00 - 16:15

Hisham Ibrahim Saeed Ibrahim (Cork, Ireland)

WS01.06 **Evaluating trends in cardiovascular events in people with cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor initiation–A retrospective review in federated electronic healthcare** 16:15 - 16:30

record

Alex Chan (Liverpool, United Kingdom)

Workshop
15:00 - 16:30 R2

WS02 - Seeing the bigger picture: regional and genetic drivers of health inequality

Lutz Naehrlich (Giessen, Germany)
Marco Zampoli (Cape Town, South Africa)

WS02.01 **Health inequality in Europe in cystic fibrosis people** 15:00 - 15:15

Isabelle Sermet-Gaudelus (Paris, France)

WS02.02 **Worldwide prevalence of F508del and rare *CFTR* variants responsive to elexacaftor-tezacaftor-ivacaftor** 15:15 - 15:30

Pierre-Régis Burgel (Paris, France)

WS02.03 **Disease Burden in people with cystic fibrosis according to CFTR genotype and eligibility to CFTR modulator therapy: a ECFS Patient Registry analysis** 15:30 - 15:45

Irene Tomarelli (Milano, Italy)

WS02.04 **Elexacaftor/tezacaftor/ivacaftor improved lung function and reduced exacerbations among individuals with rare, FDA-approved, *CFTR* variants in the United States** 15:45 - 16:00

Elizabeth Cromwell (Bethesda, United States)

WS02.05 **Assessment of respiratory infection following initiation of elexacaftor/tezacaftor/ivacaftor using the European Cystic Fibrosis Society patient registry** 16:00 - 16:15

Mordechai Pollak (Haifa, Israel)

WS02.06 **Impact of elexacaftor/tezacaftor/ivacaftor on utilisation of maintenance therapies in cystic fibrosis: Danish nationwide register study** 16:15 - 16:30

Hans Kristian Råket (Copenhagen NV, Denmark)

Workshop
15:00 - 16:30 R3

WS03 - Modernizing psychosocial assessment and care within the CFTR Modulator landscape

Johanna Gardecki (Frankfurt/Main, Germany)
Helen Love (Nottingham, United Kingdom)

WS03.01 **Caregiving burden of parents of children with Cystic Fibrosis in Ireland : The Irish Comparative Outcomes Study (ICOS)** 15:00 - 15:15

Rini Bhatnagar (Dublin, Ireland)

WS03.02 **Development and Implementation of a New Psychosocial Screening Tool -ARiSE (Achieving Routine Screen for Emotional Health) within an Outpatient Pediatric Cystic Fibrosis Practice** 15:15 - 15:30

Nadir Demirel (Rochester, United States)

WS03.03 **Mental health and sleep quality in children recieving Elexacaftor/Tezacaftor/Ivacaftor therapy** 15:30 - 15:45

Tamara Blake (South Brisbane, Australia)

WS03.04 **“You wish you could do something about it but you can’t” - understanding children’s experiences of parent’s cystic fibrosis** 15:45 - 16:00

Rachel Massey-Chase (London, United Kingdom)

WS03.05 **Development of the General Mental Health Screener (GEMS-CF): Preliminary sampling and thematic analysis of mental health concerns in a diverse group of adults with CF** 16:00 - 16:15

Beth A. Smith (Buffalo, United States)

WS03.06 **Coping and Learning to Manage Stress with CF (CALM): Preliminary results of a randomized clinical trial of adults with CF reporting mild to severe depression and/or anxiety** 16:15 - 16:30

CJ Bathgate (Denver, United States)

Workshop
15:00 - 16:30 R4

WS04 - Exploring latest breakthroughs in gastroenterology and cystic fibrosis liver disease in cystic fibrosis

Jochen G. Mainz (Brandenburg an der Havel, Germany)
Michael Wilschanski (Jerusalem, Israel)

WS04.01 **High prevalence of Hepatitis E Virus (HEV) RNA identified in Pancreatic Enzyme Replacement Therapy taken by persons with cystic fibrosis (pwCF).** 15:00 - 15:15

Barbara J. Waddell (Calgary, Canada)

WS04.02 **A novel test that identifies pancreatic enzyme replacement therapy dose-response based on breakdown of omega-3 fatty acids** 15:15 - 15:30

Steven D. Freedman (Boston, United States)

WS04.03 **Associations between nutrient intake, SCFA levels and the faecal microbiota in adults with cystic fibrosis: preliminary analysis** 15:30 - 15:45

Laura Caley (Leeds, United Kingdom)

WS04.04 **Development and Validation of the CFAbd-Score.kid, a Novel Gastrointestinal Patient-Reported Outcome Measure specific for Children with Cystic Fibrosis** 15:45 - 16:00

Pauline Sadrieh (Brandenburg an der Havel, Germany)

WS04.05 **Sustained improvement in abdominal symptoms measured by the CFAbd-Score over 2 years of treatment with Elexacaftor/Tezacaftor/Ivacaftor in people with CF aged ≥12 years: Results from the RECOVER study** 16:00 - 16:15

Paul McNally (Dublin, Ireland)

WS04.06 **The relationship between the introduction of elexacaftor/tezacaftor/ivacaftor and the number of liver or liver-lung transplantations for Cystic Fibrosis in the Eurotransplant region** 16:15 - 16:30

Marissa I. van der Spek (Groningen, Netherlands)

Workshop
15:00 - 16:30 R5

WS05 - Novel approaches and outcomes in CFTR therapeutics

Nicoletta Pedemonte (Genoa, Italy)

WS05.01 **RCT2100 rescues CFTR function in human bronchial epithelial cells and improves mucociliary clearance in CF ferrets** 15:00 - 15:15

Heather Clark (Menlo Park, United States)

WS05.02 **A Novel Uniquely Efficacious Type of CFTR Corrector with Complementary Mode of Action** 15:15 - 15:30

John Gatfield (Allschwil, Switzerland)

WS05.03 **Pharmacological improvement of CFTR function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis** 15:30 - 15:45

Simon Graeber (Berlin, Germany)

WS05.04 **SPL84 efficient and durable effect, restoring 3849 +10kb C-to-T mutated CFTR, when treated through the apical side of primary HBE cells** 15:45 - 16:00

Efrat Ozeri Galai (Jerusalem, Israel)

WS05.05 **Development of a Gene Editing Strategy to Treat Cystic Fibrosis-associated Liver Disease** 16:00 - 16:15

Daniel Prasca-Chamorro (Houston, United States)

WS05.06 **Integration of the *LacZ* and *CFTR* transgene using Find and cut-and-transfer (FiCAT)** 16:15 - 16:30

Ranmal Avinash Bandara (Toronto, Canada)

Workshop
17:00 - 18:30 R1

WS06 - Where are we with new therapeutic approaches?

Damian Downey (Belfast, United Kingdom)
George Retsch-Bogart (Chapel Hill, United States)

WS06.01 ***CFTR* transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease** 17:00 - 17:15

Jennifer Taylor-Cousar (DENVER, United States)

WS06.02 **First in Human clinical trial with SPL84, an ASO for treatment of CF patients carrying the 3849 +10 Kb C -> T mutation** 17:15 - 17:30

Eitan Kerem (Jerusalem, Israel)

WS06.03 **Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-*F508del* genotypes: a phase 3, randomised, placebo-controlled trial** 17:30 - 17:45

Isabelle Fajac (Paris, France)

WS06.04 **The expanded French Compassionate Program for use of elexacaftor-tezacaftor in people with CF with no F508del variant** 17:45 - 18:00

Pierre-Régis Burgel (Paris, France)

WS06.05 **Long-term outcomes in people with CF lacking early spirometry response to elexacaftor/tezacaftor/ivacaftor therapy** 18:00 - 18:00

Mohamad Hadhud (Jerusalem, Israel)

WS06.06 **Safety and efficacy of a nebulized phage cocktail in cystic fibrosis patients with chronic *Pseudomonas aeruginosa* pulmonary infection: a phase 1b/2a randomized, double-blind, placebo-controlled study** 18:00 - 18:15

Eitan Kerem (Jerusalem, Israel)

Workshop
17:00 - 18:30 R2

WS07 - Ageing in cystic fibrosis: diabetes, cardiovascular risk and outcomes of pregnancy

Gordon Macgregor (Glasgow, United Kingdom)

WS07.01 **Personalized CFRD prediction model can reduce OGTT frequency in low-risk individuals without delaying CFRD diagnosis** 17:00 - 17:15

Scott M. Blackman (Baltimore, United States)

WS07.02 **An induced pluripotent stem cell-based approach to elucidate the pathogenesis of cystic fibrosis related diabetes** 17:15 - 17:30

Ishika Khondaker (Houston, United States)

WS07.03 **Better β-cell glucose sensitivity is associated with residual chloride conductance of the CFTR gene in people with Cystic Fibrosis** 17:30 - 17:45

Fabiana Ciciriello (Rome, Italy)

WS07.04 **Impact of CFTR modulator therapy on cardiovascular risk in cystic fibrosis: A longitudinal cohort analysis** 17:45 - 18:00

Andrew England (Belfast, United Kingdom)

WS07.05 **Cardiometabolic risk factors in individuals with cystic fibrosis undergoing Elexacaftor / Tezacaftor / Ivacaftor therapy** 18:00 - 18:15

Gloria Leonardi (Milano, Italy)

WS07.06 **Maternal and foetal outcomes following Elexacaftor/Tezacaftor/Ivacaftor (ETI) use during pregnancy: comparison with pregnancy outcome data from the pre modulator era** 18:15 - 18:30

Christine Etherington (Leeds, United Kingdom)

Workshop
17:00 - 18:30 R3

WS08 - Optimising physiotherapy practice - insights into current management

Brenda Button (Melbourne, Australia)
Hadas Mantin (Petach Tikvah, Israel)

WS08.01 **Home sputum-induction sampling in children with Cystic Fibrosis on modulator therapy. Qualitative results on success and acceptability from CF-HomeSpIT: The Cystic Fibrosis Home Sputum Induction Trial** 17:00 - 17:15

Katherine Ronchetti (Cardiff, United Kingdom)

WS08.02 **Impact analysis of introducing an Induced Sputum Pathway at Blackpool Adult Cystic Fibrosis Service** 17:15 - 17:30

Michael Dooney (Blackpool, United Kingdom)

WS08.03 **How does Elexacaftor/Tezacaftor/Ivacaftor affect improvement in exercise capacity and body composition in adults with Cystic Fibrosis who have completed an exercise intervention?** 17:30 - 17:45

Wolfgang Gruber (Essen, Germany)

WS08.04 **Assessment of functional exercise capacity using telehealth: Reliability, validity, and usability in children with cystic fibrosis** 17:45 - 18:00

Cigdem Emirza (Istanbul, Turkey)

WS08.05 **“Framing” frailty in CF: Describing the demographics of frailty in the All Wales Adult CF population?** 18:00 - 18:15

Heather Carter (Cardiff, United Kingdom)

WS08.06 **Exercise as an airway clearance technique in cystic fibrosis: a pilot randomised controlled trial investigating acceptability and feasibility** 18:15 - 18:30

Don S Urquhart (Edinburgh, United Kingdom)

Workshop
17:00 - 18:30 R4

WS09 - New insights into cystic fibrosis microbiology

WS09.01 **Impact of long-term Elexacaftor/Tezacaftor/Ivacaftor therapy on lung infection microbiota in adults with cystic fibrosis** 17:00 - 17:15

Helen Gavillet (Newcastle Upon Tyne, United Kingdom)

WS09.02 **Biomarkers for Monitoring the Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment in People With Cystic Fibrosis** 17:15 - 17:30

Daniela Dolce (Florence, Italy)

WS09.03 **Exploring the constitution and dynamics of the cystic fibrosis sputum phageome** 17:30 - 17:45

Carson Miller (Seattle, United States)

WS09.04 **Airway microbial dynamics and inflammation: insights from the Mountain West CF Consortium's research findings** 17:45 - 18:00

Gisli Einarsson (Belfast, United Kingdom)

WS09.05 **Exploring sputum and skin secretion metabolomics for biomarkers of *Pseudomonas aeruginosa* infection in Cystic Fibrosis** 18:00 - 18:15

Simone Hadjisymeou Andreou (London, United Kingdom)

WS09.06 **Normobaric oxygen therapy augments killing of slow growing *Pseudomonas aeruginosa* by quinolones** 18:15 - 18:30

Mette Kolpen (Copenhagen, Denmark)

Special Symposium
17:00 - 18:30 R5

Best of Journal of Cystic Fibrosis, Lancet Respiratory Medicine and European Respiratory Journal

Friday, 07. June 2024

Meet the Experts
07:45 - 08:45 R6

Pharmacology and psychological side effects of modulator therapy

Anna M. Georgiopoulos (Boston, United States)
Pierre-Régis Burgel (Paris, France)

Meet the Experts
07:45 - 08:45 R6

Navigating inflammation and its resolution through the lens of CFTRm

VALERIE URBACH (CRÉTEIL, France)

Meet the Experts
07:45 - 08:45 R6

Meet the Experts

Meet the Experts
07:45 - 08:45 R6

Physiotherapy data harmonisation

Lisa Morrison (Glasgow, United Kingdom)
Jenny Hauser (Hobart, Australia)

Symposium
09:00 - 10:30 R1

***S11* - Symposium 11 - Pulmonary exacerbations**

Kris De Boeck (Leuven, Belgium)
Andrew Jones (Manchester, United Kingdom)

Understanding, measuring, and keeping tabs on exacerbations 09:00 - 09:22

Anna-Maria Dittrich (Hannover, Germany)

Artificial Intelligence for exacerbations 09:22 - 09:44

Andres Floto (Cambridge, United Kingdom)

Oral and intravenous frontiers: Guarding against complacency in the arena of home versus inpatient antibiotic treatment 09:44 - 10:06

Stéphanie Bui (Bordeaux, France)

How to STOP exacerbations in the new era? 10:06 - 10:30

Patrick Flume (Charleston, United States)

Symposium
09:00 - 10:30 R2

***S12* - Symposium 12 - Exploring novel nutritional paradigms in cystic fibrosis care: Insights from updated guidelines**

Dimitri Declercq (Ghent, Belgium)
Michael Wilschanski (Jerusalem, Israel)

Update of nutritional assessment and monitoring 09:00 - 09:22

Daina Kalnins (Toronto, Canada)

Challenges of infant nutrition in cystic fibrosis 09:22 - 09:44

Anne Munck (Paris, France)

Nutrition in the age of CFTR modulator therapy 09:44 - 10:06

Chris Smith (Brighton, United Kingdom)

New guidelines on Exocrine Pancreatic Insufficiency and 10:06 - 10:30

Pancreatic Enzyme Replacement Therapy (PERT) in cystic fibrosis

Isabelle Scheers (Brussels, Belgium)

Symposium
09:00 - 10:30 R3

***S13* - Symposium 13 - Supporting information for patients and families throughout the lifespan**

Charlotte Dawson (London, United Kingdom)
Tina D'Hondt (Jette, Belgium)

Diagnosis: The right information at the right time - supporting parents at diagnosis with different information needs (in the CFTR modulator era) 09:00 - 09:22

Paula Lomas (Bethesda, United States)

School age: Am I sick or not? - Supporting positive and negative expectations prior to starting a CFTR modulator 09:22 - 09:44

Ann Raman (Ghent, Belgium)

Adolescence: Cutting the cord - Supporting independence, and knowledge and through transition 09:44 - 10:06

Dorien Holtslag (Maastricht, Netherlands)

Adulthood: Growing older like everyone else! - Supporting the change in a post CFTR modulator world (work, relationships, pregnancy and end of life) 10:06 - 10:30

Lesley Blaikie (Inverness, United Kingdom)

Symposium
09:00 - 10:30 R4

***S14* - Symposium 14 - Mechanisms of CFTR modulation: what do we know and what is still missing?**

László Csanády (Budapest, Hungary)
Nicoletta Pedemonte (Genoa, Italy)

Using structure modeling and functional biophysics to unravel CFTR modulator mechanisms 09:00 - 09:22

Tzyh-Chang Hwang (Columbia, United States)

Allosteric correction of CFTR variants by small molecules 09:22 - 09:44

Tamas Hegedus (Budapest, Hungary)

Acting on CFTR membrane-spanning domain interfaces to rescue misfolded variants 09:44 - 10:06

Isabelle Callebaut (Paris, France)

Modulator-based restoration of chloride versus bicarbonate transport in cystic fibrosis 10:06 - 10:30

Paola Vergani (London, United Kingdom)

Symposium
09:00 - 10:30 R5

***S15* - Symposium 15 - Capturing data from people living with CFTR related disorders: when, why and how?**

Nicholas Simmonds (London, United Kingdom)
Isabelle Sermet-Gaudelus (Paris, France)

Understanding CFTR related disorders - which outcomes should be collected and for how long? 09:00 - 09:22

Carlo Castellani (Genoa, Italy)

The spectrum of cystic fibrosis and CFTR-related disease in Japan 09:22 - 09:44

Diagnostic overead/oversight and reclassification in cystic fibrosis registries 09:44 - 10:06

Alexander Elbert (Bethesda, United States)

Reclassification and cystic fibrosis diagnosis reversal – (from a psychological/clinical perspective) 10:06 - 10:30

Michele Puckey (London, United Kingdom)

Symposium
11:00 - 12:30 R1

***S16* - Symposium 16 - How to adapt to changes in life expectancy?**

Scott Bell (Chermside, Australia)
Harriet Corvol (Paris, France)

Psychological adjustment to modulator therapy: a holistic view 11:00 - 11:22

Trudy Havermans (Leuven, Belgium)

How does change in life expectancy impact on genetic counselling? 11:22 - 11:44

Julia Hentschel (Leipzig, Germany)

Late complication prevention and management - starting from birth and after... 11:44 - 12:06

Barry Plant (Cork, Ireland)

Patient and public involvement in cystic fibrosis health research from a cystic fibrosis patient group perspective 12:06 - 12:30

Audrey Chansard (Paris, France)

Symposium
11:00 - 12:30 R2

***S17* - Symposium 17 - Clinical trial endpoints in children aged under two years**

Tim Lee (Leeds, United Kingdom)
Hettie Janssens (Rotterdam, Netherlands)

Lung function in infants under two years: what test should we select and why? 11:00 - 11:22

Mirjam Stahl (Berlin, Germany)

Chest CT and MRI as endpoints for CF lung disease in infants under 2 years: which one is best? 11:22 - 11:44

Exploratory endpoints of infection and inflammation in infants: what is useful? 11:44 - 12:06

Paul McNally (Dublin, Ireland)

Non-pulmonary endpoints for infants: what is of clinical importance? 12:06 - 12:30

Isabelle Sermet-Gaudelus (Paris, France)

Symposium
11:00 - 12:30 R3

***S18* - Symposium 18 - Exploring the resilient terrain: insights into bacterial persistence in cystic fibrosis**

Jean-Luc Mainardi (Paris, France)
Laura Sherrard (Belfast, United Kingdom)

Metabolism and persistence: unraveling the link between metabolic pathways and microbial survival 11:00 - 11:22

Ruggero La Rosa (Lyngby, Denmark)

Unveiling the persistence of *Staphylococcus aureus*: insights into antibiotic tolerance mechanisms 11:22 - 11:44

Francoise van Bambeke (Brussels, Belgium)

Unmasking the persistence of *Mycobacterium abscessus* in cystic 11:44 - 12:06

fibrosis lungs

Nicola Ivan Lorè (Milan, Italy)

Adaptation and pathogenicity of *Achromobacter spp.* during cystic fibrosis lung disease 12:06 - 12:30

Lisa Påhlman (Lund, Sweden)

Symposium
11:00 - 12:30 R4

***S19* - Symposium 19 - Emerging alternative targets for cystic fibrosis therapeutics**

Pascale Fanen (Créteil, France)
David Sheppard (Bristol, United Kingdom)

Modulation of ribosome speed and fidelity to rescue refractory CF-causing variants 11:00 - 11:22

Kathryn Oliver (Atlanta, United States)

Novel regulators to enhance CFTR trafficking and membrane stability 11:22 - 11:44

Paulo Matos (Lisbon, Portugal)

Inhibition of ATP12A to rectify airway surface liquid acidification in cystic fibrosis 11:44 - 12:06

Luis Galietta (Pozzuoli, Italy)

Solute carrier proteins as potential therapeutic targets in cystic fibrosis 12:06 - 12:30

John Hanrahan (Montreal, Canada)

Symposium
11:00 - 12:30 R5

***S20* - Symposium 20 - Providing clear advice to families and children with CFSPID**

Louise Thomson (Glasgow, United Kingdom)
Karen Raraigh (Baltimore, United States)

How does CAVD population genetic data guide the information we give to CFSPID families 11:00 - 11:22

Emmanuelle Girodon (Paris, France)

How do we communicate the risk to conversion to a CF diagnosis to CFSPID families? 11:22 - 11:44

Kevin Southern (Liverpool, United Kingdom)

A well six year old CFSPID child with a normal sweat test can be discharged to their primary care physician (PRO) 11:44 - 12:02

Jürg Barben (St. Gallen, Switzerland)

A well six year old CFSPID child with a normal sweat test can be discharged to their primary care physician (CON) 12:02 - 12:20

Deanna Green (St Petersburg, United States)

Discussion 12:20 - 12:30

ePoster Session
14:00 - 15:00 R3

ePoster Session 10 - Modulation of CFTR: from bench to bedside

Carlos M Farinha (Lisboa, Portugal)
Clémence Martin (Paris, France)

EPS10.01 **Co-Potentiation of p.Arg334Trp-CFTR by VX-770 with Novel Small Molecules** 14:00 - 14:06

Miquéias Lopes-Pacheco (Lisbon, Portugal)

EPS10.02 **Gene expression profiles of intestinal organoids from patients with cystic fibrosis upon their exposure to elexacaftor/tezacaftor/ivacaftor (ETI)** 14:06 - 14:12

Tereza Dousova (Prague, Czech Republic)

EPS10.03 **Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties in children with Cystic Fibrosis** 14:12 - 14:18

Oriane Burgun (Paris, France)

EPS10.04 **Low-frequency oscillometry indices to assess the effect of elexacaftor/texacaftor/ivacaftor in comparison to multiple breath washout parameters among young people with CF** 14:18 - 14:24

Elpis Hatziagorou (Thessaloniki, Greece)

EPS10.05 **Measuring segmental lung changes of cystic fibrosis patients before and after elexacaftor-tezacaftor-ivacaftor (ETI) with an automated analysis method** 14:24 - 14:30

Ieva Aliukonyte (Rotterdam, Netherlands)

EPS10.06 **Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis** 14:30 - 14:36

Manu Jain (Chicago, United States)

EPS10.07 **Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: Same-same but different?** 14:36 - 14:42

Hannah Karimzadeh (Liverpool, United Kingdom)

EPS10.08 **LONGITUDE: an observational study of the long-term effectiveness of ELX/TEZ/IVA in people with CF using data from the UK CF Registry—preliminary results from the subgroup aged 6–11 years** 14:42 - 14:48

Gabriela Vega-Hernandez (London, United Kingdom)

EPS10.09 **Positive and Negative Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparison of Healthcare Providers' Observations in Europe vs US** 14:48 - 14:54

Sonia Graziano (Rome, Italy)

EPS10.10 **Elexacaftor/tezacaftor/ivacaftor remains inaccessible for people with cystic fibrosis in low- and middle-income countries: how can this be solved?** 14:54 - 15:00

Jonathan Guo (London, United Kingdom)

ePoster Session
14:00 - 15:00 R6

ePoster Session 7 - Inflammation and pulmonary outcomes in cystic fibrosis

Malcolm Brodlie (Newcastle, United Kingdom)

EPS7.01 **A survey of United States cystic fibrosis physicians' perspectives on lung transplant referral in the era of highly effective modulator therapy** 14:00 - 14:06

Kathleen Ramos (Seattle, United States)

EPS7.02 **CFTR modulation is not an independent determinant of the visco-elastic properties of sputum in cystic fibrosis** 14:06 - 14:12

Iris Janssens (Ghent, Belgium)

EPS7.03 **Evaluating a novel MRI measure of lung ventilation in 6 to 11 year olds before and after elexacaftor/tezacaftor/ivacaftor: Preliminary results from the CIFT-CF Junior study** 14:12 - 14:18

Alexander Yule (Nottingham, United Kingdom)

EPS7.04 **Sinus MRI demonstrates sustained treatment response in children after Elexacaftor/Tezacaftor/Ivacaftor (E/T/I) therapy of a similar magnitude to oxygen-enhanced (OE-) lung MRI** 14:18 - 14:24

Christopher Short (London, United Kingdom)

EPS7.05 **Impact of triple CFTR modulator therapy on hospital admissions at a large cystic fibrosis adult centre: a 3-year review** 14:24 - 14:30

Lucy E Wadsworth (Manchester, United Kingdom)

EPS7.06 **Cardiovascular function in people with cystic fibrosis established on Elexacaftor/Tezacaftor/Ivacaftor modulator therapy** 14:30 - 14:36

Lauren Clayton (Portsmouth, United Kingdom)

EPS7.07 **Exploring the relationship of compartmentalised inflammation to structural and functional lung disease in CF: the mysterious dichotomy of IL-6** 14:36 - 14:42

Teresa Fuchs (London, United Kingdom)

EPS7.08 **Improved diagnosis of early aspergillus lung disease in cystic fibrosis (IDEAL)** 14:42 - 14:42

Federico Mollica (Rotterdam, Netherlands)

EPS7.09 **Prospective study on early detection and immune response in patients with CF and acute ABPA** 14:42 - 14:48

Carsten Schwarz (Potsdam, Germany)

EPS7.10 ***Cystic fibrosis related diabetes is associated with increased airway inflammation*** 14:48 - 14:54

Stefanie Diemer (Lund, Sweden)

ePoster Session
14:00 - 15:00 R6

ePoster Sessions 7 - 9

ePoster Session
14:00 - 15:00 R6

ePoster Session 8 - Evolution of physiotherapy in the post ETI era

Jenny Hauser (Hobart, Australia)
Gemma Stanford (London, United Kingdom)

EPS8.01 **An analysis of the use of non-invasive ventilation pre and post Kaftrio® in a large UK adult Cystic Fibrosis (CF) centre** 14:00 - 14:06

Charlotte Morby (Birmingham, United Kingdom)

EPS8.02 **Evolving physiotherapy Airway Clearance Technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era** 14:06 - 14:12

Kleine Leonardia (London, United Kingdom)

EPS8.03 **Impact of 12 months of elexacaftor/tezacaftor/ivacaftor on pulmonary function and exercise capacity in patients with cystic fibrosis** 14:12 - 14:18

Josef Jägerstedt (Stockholm, Sweden)

EPS8.04 **“To test or not to test” – exercise testing as an assessment of frailty in CF** 14:18 - 14:24

Heather Carter (Cardiff, United Kingdom)

EPS8.05 **A case series of Muscle strength and Body Composition from no modulator to highly effective modulator (ETI) in Adults with Cystic Fibrosis** 14:24 - 14:30

Clare M Reilly (Dublin, Ireland)

EPS8.06 **“ ’Snot a problem”: Physiotherapy outcomes from initiating elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis post-lung transplant** 14:30 - 14:36

Rachel McDowell (Cardiff, United Kingdom)

EPS8.07 **RExA- CF - A pilot study assessing the acceptability and** 14:36 - 14:42

comparability of the results of remote video exercise tests to face-to-face exercise tests for adults with cystic fibrosis

Gemma Stanford (London, United Kingdom)

EPS8.08 **MUSCULOSKELETAL PAIN AND REGIONAL INTERDEPENDENCE IN CYSTIC FIBROSIS** 14:42 - 14:48

Niklas Sinderholm Sposato (Gothenburg, Sweden)

EPS8.09 **Correlation between sweat test response to modulator therapy and lung function response can identify and distinguish between non-compliant patients and compliant patients with poor clinical response** 14:48 - 14:54

Hannah Morgan (Cardiff, United Kingdom)

EPS8.10 **Evaluating the extent and presenting symptoms of breathing pattern disorder diagnosis and physiotherapy outcomes in an adult Cystic Fibrosis centre** 14:54 - 15:00

Nicky Mills (Leicester, United Kingdom)

ePoster Session
14:00 - 15:00 R6

ePoster Session 9 - Understanding CFTR function and developing new treatment targets

David Sheppard (Bristol, United Kingdom)
Marianne S. Carlon (Leuven, Belgium)

EPS9.01 **Utilizing intestinal organoids to assess in-vitro responses to CFTR modulators in rare *CFTR* variants** 14:00 - 14:06

Liron Birimberg-Schwartz (Jerusalem, Israel)

EPS9.02 **A tool for unraveling bicarbonate transport: monitoring CFTR-mediated ion-channel function with anion-sensitive YFP and pH-sensitive pHuji** 14:06 - 14:12

Jyosthna Lunavath (London, United Kingdom)

EPS9.03 **Precising personalized medicine in Cystic Fibrosis through single-cell functional profiling of Cystic Fibrosis Transmembrane Conductance Regulator** 14:12 - 14:18

Kavisha Arora (Los Angeles, United States)

EPS9.04 **Lung epithelial 3D Air-Liquid-Interface culture systems for high-resolution investigations of bacterial infection dynamics during treatment with elexacaftor/tezacaftor/ivacaftor (ETI)** 14:18 - 14:24

Maria Pals Bendixen (Copenhagen, Denmark)

EPS9.05 **Multiomic approach to identify possible mechanisms of action of CFTR modulator therapies and to propose new therapeutic targets** 14:24 - 14:30

Mairead Kelly-Aubert (Paris, France)

EPS9.06 **Elexacaftor/tezacaftor/ivacaftor restore stability, but not wild-type-like channel gating to the F508del-CFTR Cl^- channel** 14:30 - 14:36

Mayuree Rodrat (Bristol, United Kingdom)

EPS9.07 **Investigation of CFTR function and epithelial barrier properties at single cell resolution using multi-electrode array technology** 14:36 - 14:42

Marjolein Ensinck (Leuven, Belgium)

EPS9.08 **A modelling framework for epithelial airway fluid and ion transport with multiple cell types: implications for success or failure in gene therapies for cystic fibrosis** 14:42 - 14:48

Omar Hamed (London, United Kingdom)

EPS9.09 **Designing CFTR modulators based on the antagonists of Type IV ABC transporters** 14:48 - 14:54

Maria-Cristina Ardelean (London, United Kingdom)

EPS9.10 **CFTR F508 mutation influences airway expression profile of miRNAs and their isomirs in children with cystic fibrosis** 14:54 - 15:00

Aleksandra Szczepankiewicz (Poznan, Poland)

Poster Viewing
14:00 - 15:00

Poster Viewing 2

P102 **Methicillin-Resistant Staphylococcus aureus and pulmonary outcome in people with cystic fibrosis: a European cystic fibrosis patient registry data analysis** 14:00 - 14:00

Dario Prais (Petah Tikva, Israel)

P103 **Changing prevalence of methicillin sensitive *Staphylococcus aureus* in children with Cystic Fibrosis (CF) over last six years – A single centre experience** 14:00 - 14:00

Sajeevan Rasanantham (Middlesbrough, United Kingdom)

P104 **Definitions of Pulmonary Exacerbation in People with Cystic Fibrosis: a scoping review** 14:00 - 14:00

Malcolm Brodlie (Newcastle, United Kingdom)

P105 **Patient reported outcomes in people with CF taking elexacaftor/tezacaftor/ivacaftor (ETI) in the Home-Reported Outcomes (HERO-2) study** 14:00 - 14:00

Clement Ren (Philadelphia, United States)

P106 **Monitoring the adverse drug reactions after elexacaftor/tezacaftor/ivacaftor therapy in the Cystic Fibrosis cohort** 14:00 - 14:00

Cristina Chellin (Verona, Italy)

P107 **Efficacy of Elaxacaftor/Tezacaftor/Ivacaftor after market authorisation in children and adults with CF** 14:00 - 14:00

Eugénie Noémie Rachel Collaud (Zurich, Switzerland)

P108 **Describing trends in cystic fibrosis transmembrane conductance regulator modulator (CFTRm) use in people with cystic fibrosis (PwCF) using real-world Cystic Fibrosis Registry of Ireland (CFRI) data** 14:00 - 14:00

Paul O'Regan (Dublin, Ireland)

P109 **Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with Cystic Fibrosis and at least one F508del allele: a retrospective Italian multicenter study** 14:00 - 14:00

Vito Terlizzi (Florence, Italy)

P110 **Maintaining equity and quality of cystic fibrosis care: a roadmap for Scotland** 14:00 - 14:00

Jana Witt (London, United Kingdom)

P111 **The role of the registry in planning targeted therapy and assessing its effectiveness and safety** 14:00 - 14:00

Elena Kondratyeva (Moscow, Russian Federation)

P112 **Real-time estimation of individual long- and short-term lung functions trends in persons with cystic fibrosis within the Swedish cystic fibrosis registry** 14:00 - 14:00

Marcus Svedberg (Gothenburg, Sweden)

P113 **Mediation analysis investigating potential determinants of the survival gap between the sexes in cystic fibrosis; a complex picture** 14:00 - 14:00

Katherine P Holdsworth (London, United Kingdom)

P114 **SOCIAL DETERMINANTS OF HEALTH IN CYSTIC FIBROSIS** 14:00 - 14:00

Neval Metin Cakar (Istanbul, Turkey)

P115 **A retrospective analysis of the ECFSPR to characterise the pulmonary phenotype and use of intravenous antibiotics in people with cystic fibrosis harbouring Bi-allelic CFTR class 1 mutations** 14:00 - 14:00

Annalisa Orenti (Milan, Italy)

P116 **How does the 4005+2T>C *CFTR variant* influence disease severity in the Norwegian cystic fibrosis population** 14:00 - 14:00

Audun OS (Oslo, Norway)

P117 **The variation in cystic fibrosis transmembrane conductance regulator variants in Canada and around the world** 14:00 - 14:00

Stephanie Y. Cheng (Toronto, Canada)

P118 **Rare CFTR variants: knowing them to target them more successfully** 14:00 - 14:00

Raphael Chiron (Montpellier, France)

P119 **Improving cystic fibrosis care in Jordan through quality improvement initiatives in collaboration with U.S. Cystic Fibrosis Centers** 14:00 - 14:00

Ahmet Uluer (Boston, United States)

P120 **Utilisation of multiple breath washout in Europe differs substantially between age groups and countries** 14:00 - 14:00

Lutz Naehrlich (Giessen, Germany)

P121 **Updating the UK Cystic Fibrosis Registry's genotype cleaning processes and minimising free-text to improve data quality** 14:00 - 14:00

Francis Adams (London, United Kingdom)

P122 **The quality of the data in the European Cystic Fibrosis Society Patient Registry as assessed through source data verification from 2018-2024** 14:00 - 14:00

Vibha Prasad (Giessen, Germany)

P123 **Establishing a Cystic Fibrosis Learning Network for Low and Middle-Income Countries** 14:00 - 14:00

Hector Gutierrez (Birmingham, United States)

P124 **Assessment of the impact of the Newborn Screening Programme on Lung Function in Children with Cystic Fibrosis in Ireland : The Irish Comparative Outcomes Study (ICOS)** 14:00 - 14:00

Rini Bhatnagar (Dublin, Ireland)

P125 **Development of a holistic feedback package to support quality improvement in cystic fibrosis centres in the UK** 14:00 - 14:00

Fiona McKirdy (London, United Kingdom)

P126 **Who are we? An analysis of the social demographics of people with CF attending a large adult centre in the North of England** 14:00 - 14:00

Fiona Dowdall (Manchester, United Kingdom)

P127 **A quality improvement project supported by a new holistic QI offer, to improve the annual review process** 14:00 - 14:00

Fiona McKirdy (London, United Kingdom)

P128 **Comparison of reporting quality in national cystic fibrosis patient registries: Implications for identifying use of novel CFTR modulators** 14:00 - 14:00

Owen William Tomlinson (Exeter, United Kingdom)

P129 **Challenges and innovations in cystic fibrosis clinical teams: insights from the Cystic Fibrosis Trust staffing tool** 14:00 - 14:00

Jana Witt (London, United Kingdom)

P130	**Developing a study protocol to assess the feasibility and acceptability of implementing Patient Reported Outcome Measures in the Cystic Fibrosis Registry of Ireland**	14:00 - 14:00
Robyn Doherty (Dublin, Ireland)		
P131	**Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry**	14:00 - 14:00
Elliot McClenaghan (London, United Kingdom)		
P132	**Learning from registries: differences in prevalence of CF related diabetes between Dutch CF centres**	14:00 - 14:00
Domenique Zomer-van Ommen (Baarn, Netherlands)		
P133	**Presence of coronary calcium as a marker of coronary disease risk in adults with cystic fibrosis: a single centre study**	14:00 - 14:00
Gregory Gibson (London, United Kingdom)		
P134	**Single centre experience of pregnancies in the post CFTR modulator era.**	14:00 - 14:00
Bryony Miller (Nottingham, United Kingdom)		
P135	**Analysis of the frequency of complications in cystic fibrosis: dynamics over 10 years according to the national register**	14:00 - 14:00
Anna Voronkova (Moscow, Russian Federation)		
P136	**Timing of transplantation does not influence the severity of SARS-CoV-2 Infection in the Cystic Fibrosis Population**	14:00 - 14:00
Yumi Naito (London, United Kingdom)		
P137	**Clinical characteristics of adult cystic fibrosis (CF) patients in Kazakhstan**	14:00 - 14:00
Elena Amelina (Moscow, Russian Federation)		
P138	**An argentinian multicentre report on patients with cystic fibrosis over the age of 40 years**	14:00 - 14:00
Ezequiel Baran (La Plata, Argentina)		
P139	**Genetic characteristics of patients with CF according to the Russian Federation Registry 2021**	14:00 - 14:00
Elena Kondratyeva (Moscow, Russian Federation)		
P140	**This abstract is a study that investigates demographic and anthropometric changes, the relationship between variables and survival analyses of people with cystic fibrosis by years**	14:00 - 14:00
Seyda Karabulut (Istanbul, Turkey)		
P141	***CFTR* gene variants in the Croatian Database of People with Cystic Fibrosis**	14:00 - 14:00
Lana Omerza (Zagreb, Croatia)		
P142	**Prognostic factors reflecting survival of patients with cystic fibrosis (CF)**	14:00 - 14:00
Oksana G. Zonenko (Moscow, Russian Federation)		
P197	**Metaproteomic Profile of the Respiratory Microbiota in Patients with Cystic Fibrosis Infected by *Mycobacterium abscessus*: A Tale of Two Patients**	14:00 - 14:00
Lucia Grenga (Bagnols-sur-Cèze, France)		
P198	**Phenotypic and genotypic characterization of *Mycobacterium abscessus complex* in Cystic Fibrosis patients**	14:00 - 14:00
Maria Francesca Liporace (Milan, Italy)		
P199	**Potential Impact of Elexacaftor/Tezacaftor/Ivacaftor on Successful Eradication of *Mycobacterium abscessus* in a Boy with CF and the**	14:00 - 14:00

F508del/F508del Genotype: a Case Report

Marcela Kreslová (Pilsen, Czech Republic)

P200 **"Galactomannan Gold? Unveiling Aspergillus Infections in Cystic Fibrosis Children"** 14:00 - 14:00

Simone Hadjisymeou Andreou (London, United Kingdom)

P201 **Clinical significance of mucor in airway culture of immunocompetent patients with CF and other chronic lung diseases** 14:00 - 14:00

Michal Gur (Haifa)

P202 **Metabolism as a mediator of trimethoprim/sulfamethoxazole-induced cell death in *Staphylococcus aureus*** 14:00 - 14:00

Lauren Gonsalves (Seattle, United States)

P203 **Unraveling antibiotic resistance mechanisms and dynamics of resistant *Staphylococcus aureus* isolates during chronic airway infection in people with cystic fibrosis** 14:00 - 14:00

Claudia Färber (Münster, Germany)

P204 ***Staphylococcus aureus* population structure and the incidence of methicillin-resistant *S. aureus* (MRSA) and Panton-Valentine Leucocidin (PVL) toxin among cystic fibrosis patients in two CF centres** 14:00 - 14:00

Dervla TD Kenna (London, United Kingdom)

P205 **Chronic coinfection of *Staphylococcus aureus* and *Pseudomonas aeruginosa* in people with cystic fibrosis – a retrospective 2 center study and Investigation of the bacterial interaction status** 14:00 - 14:00

Maria Magdalena Peters (Münster, Germany)

P206 **Competition of mucoid *Staphylococcus argenteus* and *Staphylococcus aureus* in the lungs of a person with cystic fibrosis** 14:00 - 14:00

Christine Rumpf (Münster, Germany)

P207 **The longitudinal assessment of anti-virulence gene expression in *Pseudomonas aeruginosa* grown in cystic fibrosis sputum mimics** 14:00 - 14:00

Tegan Hibbert (Liverpool, United Kingdom)

P208 **A novel glycan-binding boronic acid-polyethyleneimine (PEI) conjugate compound can interfere with *Pseudomonas aeruginosa* biofilm formation** 14:00 - 14:00

Andrew Marshall (Belfast, United Kingdom)

P209 **Mucus composition and interactions with *Pseudomonas aeruginosa* in chronically infected cystic fibrosis and primary ciliary dyskinesia patients** 14:00 - 14:00

Maja Valentin Kragh (København Ø, Denmark)

P210 **Isolation frequency and abundance of *Pseudomonas aeruginosa (Pa)* in people with CF with chronic pseudomonas infection decreases following initiation of elexacaftor/tezacaftor/ivacaftor (ETI)** 14:00 - 14:00

John King (London, United Kingdom)

P211 **Evolutionary adaptation of *Burkholderia multivorans* to enacyloxin IIa leads to alterations in antimicrobial resistance and phenotype** 14:00 - 14:00

Lucile Hubert (Cardiff, United Kingdom)

P212 **Impact of ELX/TEZ/IVA on rates of chronic and intermittent Pseudomonas aeruginosa infection within a Regional Children's Cystic Fibrosis Centre** 14:00 - 14:00

Sophie Chereau (Leeds, United Kingdom)

P213 **Determination of metallo-β-lactamase genes Pseudomonas** 14:00 - 14:00

aeruginosa isolated from chronic lung infection in CF patients

Ekaterina A. Siyanova (Moscow, Russian Federation)

P214 **Quantitative variability in *Pseudomonas aeruginosa* sputum density among chronically infected patients** 14:00 - 14:00

Thomas Bryrup (Copenhagen, Denmark)

P215 **Effect of ivacaftor on the fractional inhibitory concentration values of antibiotic combinations used in the treatment of *Pseudomonas aeruginosa* in cystic fibrosis** 14:00 - 14:00

Sinead Warren (Glasgow, United Kingdom)

P216 **Determination of the minimum inhibitory concentration of biapenem against strains of Pseudomonas aeruginosa isolated from the respiratory tract of patients with cystic fibrosis** 14:00 - 14:00

Marina Chernukha (Moscow, Russian Federation)

P217 **Health implication of the COVID-19 pandemic for children with Cystic Fibrosis (CF) followed at CF center Copenhagen** 14:00 - 14:00

Marika Nathalie Schmidt (Copenhagen, Denmark)

P218 **Contact-dependent inhibition systems are broadly distributed in *Stenotrophomonas maltophilia* and display antibacterial properties** 14:00 - 14:00

Cristian Crisan (Atlanta, United States)

P219 **Identification of putative antigens in *Achromobacter xylosoxidans*** 14:00 - 14:00

Cecilia Sahl (Lund, Sweden)

P220 **Increased incidence of *Mycoplasma pneumoniae* in a Regional Paediatric Cystic Fibrosis Centre** 14:00 - 14:00

Laura Jenkins (Belfast, United Kingdom)

P221 **Airways viral infections in children and adults with Cystic Fibrosis** 14:00 - 14:00

Silvia Campana (Florence, Italy)

P222 **AIRWAY *ACHROMOBACTER XYLOSOXIDANS* AND DISEASE SEVERITY IN CYSTIC FIBROSIS** 14:00 - 14:00

Dario Prais (Petah Tikva, Israel)

P223 **Detection of Pneumocystis jirovecii in patients with cystic fibrosis in Russian Federation** 14:00 - 14:00

Lusine Avetisyan (Moscow, Russian Federation)

P224 **Vaccine derived *Bordetella bronchioseptica* causing clinical disease in a child living with cystic fibrosis: a cautionary tale of live vaccine use in companion animals** 14:00 - 14:00

Jacob Brolly (Newcastle upone Tyne, United Kingdom)

P225 **Colonisation of a 4-month-old cystic fibrosis child by *Burkholderia cenocepacia*: treatment adaptation after relapse and strains genomic comparison** 14:00 - 14:00

Bastien Baud (Montpellier, France)

P226 **Pulmonary infection caused by Dyella species in cystic fibrosis** 14:00 - 14:00

Christine Ronne Hansen (Lund, Sweden)

P227 **Life threatening infection with a highly resistant Achromobacter xylosoxidans strain** 14:00 - 14:00

Julia Sobel (Erlangen, Germany)

P228 **Multicentre review of lung microbiome for patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor** 14:00 - 14:00

Silvie Hitmarova (Liverpool, United Kingdom)

P229 **Do CFTR modulators interfere with microbiological diagnosis?** 14:00 - 14:00

Geneviève Héry-Arnaud (Brest, France)

P230 **Real-life impact on elexacaftor/tezacaftor/ivacaftor (ETI) on sputum microbiology in a large adult cystic fibrosis (CF) unit** 14:00 - 14:00

Emma Abel (Leeds, United Kingdom)

P231 **Sustained reductions CF pathogen burden in children treated with ELX/TEZ/IVA** 14:00 - 14:00

Karen Keown (Belfast, United Kingdom)

P232 **Accessing impact of Elexacaftor/Tezacaftor/Ivacaftor therapy on antibiotic usage in an adult cystic fibrosis population** 14:00 - 14:00

Valerie Mills (Belfast, United Kingdom)

P233 **Microbial pathogens alterations in induced sputum following highly effective CFTR modulator therapy in children with cystic fibrosis (aged 6-12 years)** 14:00 - 14:00

Gaja Setnikar Kimovec (Ljubljana, Slovenia)

P234 **Changes in bacteriologic isolates from pediatric cystic fibrosis patients before and after treatment with CFTR modulators** 14:00 - 14:00

Cintia Antonioli (La Plata, Argentina)

P235 **Microbiological parameters in respiratory samples of patients with cystic fibrosis before and after being treated with elexacaftor/tezacaftor/ivacaftor** 14:00 - 14:00

María Soledad Zapico-González (Oviedo, Spain)

P236 **Investigating the impact of elexacaftor/tezacaftor/ivacaftor therapy on longitudinal oropharyngeal microbiome dynamics in children with cystic fibrosis** 14:00 - 14:00

Drake C. Bouzek (Seattle, United States)

P237 **Antimicrobial Activity of ceftolozane/tazobactam, ceftazidime/avibactame an cefiderocol against *Burkholderia cepacia* complex species from cystic fibrosis patients** 14:00 - 14:00

Michael Hogardt (Frankfurt, Germany)

P238 **Exploring the probiotic potential of *Lacticaseibacillus casei* AMBR2 for cystic fibrosis *in vitro*** 14:00 - 14:00

Joke Bastiaenssen (Antwerp, Belgium)

P239 **Review of antimicrobial courses prescribed in paediatric patients with Cystic Fibrosis pre and post CFTR modulators** 14:00 - 14:00

Vandana Pankhania (Leicester, United Kingdom)

P240 **Clinical outcomes and healthcare utilization of patients with cystic fibrosis from the study of prescribing patterns and effectiveness of Ceftolozane/Tazobactam (C/T) real-world analysis (SPECTRA)** 14:00 - 14:00

Mike Allen (London, United Kingdom)

P241 **Safety and efficacy of meropenem-vaborbactam in people with cystic fibrosis (pwCF)** 14:00 - 14:00

Mohammad Abdalaziz (Leeds, United Kingdom)

P242 **Hearing test and aminoglycoside ototoxicity mutation screening in a paediatric network clinic cohort treated with IV aminoglycosides** 14:00 - 14:00

Clare Onyon (Worcester, United Kingdom)

P243 **Prevalence of genetic determinants of antibiotic resistance in patients with cystic fibrosis in the Moscow region** 14:00 - 14:00

Elena Kondratyeva (Moscow, Russian Federation)

P244 **Why did we start dry powder inhaled antibiotics and what were patients' experiences with them?** 14:00 - 14:00

Rebecca Wollerton (Plymouth, United Kingdom)

P245 **A therapeutic piperacillin and meropenem serum concentration monitoring reveals suboptimal pharmacodynamic (PD) response in standard therapeutic regimes** 14:00 - 14:00

Nela Šťastná (Brno, Czech Republic)

P246 **Case report: use of the novel oral fluoroquinolone delafloxacin in cystic fibrosis** 14:00 - 14:00

Michael Dooney (Blackpool, United Kingdom)

P247 **Advances in cystic fibrosis lung Infection modeling: profiling microbial interactions at micro-scale distances** 14:00 - 14:00

Sarah Fusco (Kongens Lyngby, Denmark)

P248 **Age-related features of the microbial flora in pediatric patients with cystic fibrosis in the Moscow region** 14:00 - 14:00

Elena Kondratyeva (Moscow, Russian Federation)

P249 **Age-specific Changes in Gut Microbial Diversity in Cystic Fibrosis: A Meta-analysis** 14:00 - 14:00

Blanka Bódy (Budapest, Hungary)

P250 **An information leaflet about *MT-RNR1* testing to reduce the risk of aminoglycoside-induced hearing loss in people with cystic fibrosis** 14:00 - 14:00

Alison Taylor (London, United Kingdom)

P251 **Analysis of screening for the m.1555A>G mutation at annual review** 14:00 - 14:00

Michael Dooney (Blackpool, United Kingdom)

P252 **Artificial Intelligence and General Data Protection Regulation-Compliant Synthetic Data. Generation for CF Enhanced Diagnosis and Personalized Treatment** 14:00 - 14:00

Maria Dolores Pastor-Vivero (Barakaldo, Spain)

P253 **Assessing feasibility, acceptability, and accuracy of self-obtained respiratory cultures for cystic fibrosis patients across multiple clinics in the United States** 14:00 - 14:00

Christopher Siracusa (Cincinnati, United States)

P254 **Bacterial flora of the lower respiratory tract in cystic fibrosis patients from North Caucasus** 14:00 - 14:00

Ekaterina Samoylova (Moscow, Russian Federation)

P255 **Comparison of the respiratory tract microflora of patients with cystic fibrosis and primary ciliary dyskinesia** 14:00 - 14:00

E. A. Domblides (Moscow, Russian Federation)

P256 **Current utility of sampling respiratory microbiology in children with cystic fibrosis using oropharyngeal swabs: Insights from the BEGIN study** 14:00 - 14:00

Christopher E. Pope (Seattle, United States)

P257 **Development and validation of a machine learning model to predict antimicrobial resistance in people living with cystic fibrosis using routinely collected electronic healthcare record data** 14:00 - 14:00

Freddy Frost (Liverpool, United Kingdom)

P258 **Development of a liquid polymicrobial biofilm model for preclinical testing of novel cystic fibrosis therapeutics** 14:00 - 14:00

Hollie Leighton (Liverpool, United Kingdom)

P259 **Effects of modulator treatments on microbiological results, pulmonary function tests and quality of life respiratory symptom scores in children with cystic fibrosis** 14:00 - 14:00

Didem Alboğa (Ankara, Turkey)

P260 **Experience in assessing the antibacterial properties of copper,** 14:00 - 14:00

superhydrophilic and superhydrophobic coatings in a hospital setting

Marina Chernukha (Moscow, Russian Federation)

P261 **INFECTION PREVENTION AND CONTROL IN CYSTIC FIBROSIS: AN UPDATE OF A SYSTEMATIC REVIEW OF INTERVENTIONS** 14:00 - 14:00

Nicola Rowbotham (Nottingham, United Kingdom)

P262 **Lack of association between antibiotic regimen spectrum and pulmonary exacerbation treatment responses** 14:00 - 14:00

Ranjani Somayaji (Calgary, Canada)

P263 **Shotgun metagenomic sequencing for more precise pathogen detection within the cystic fibrosis microbiome** 14:00 - 14:00

Eline Cauwenberghs (Antwerpen, Belgium)

P264 **Standard culture-based approaches for cell enumeration are not reliable for quantifying viable cells in biofilms of cystic fibrosis isolates** 14:00 - 14:00

Micaela Mossop (London, United Kingdom)

P265 **To spit or not to spit? Sputum induction testing in children with Cystic Fibrosis** 14:00 - 14:00

Niamh Galway (Belfast, United Kingdom)

P266 **Elexacaftor/tezacaftor/ivacaftor: real world data on adverse events reported at one UK adult cystic fibrosis centre** 14:00 - 14:00

Clare Horton-Smith (Nottingham, United Kingdom)

P267 **Trends in liver health indices in paediatric patients with Cystic Fibrosis: improving real world assessment and early detection of cirrhosis** 14:00 - 14:00

Jenny Marwick (Edinburgh, United Kingdom)

P268 **EVOLUTION OF HEPATOBILIARY INVOLVEMENT IN CYSTIC FIBROSIS CHILDREN ON CFTR MODULATORS** 14:00 - 14:00

Mélanie Auvray (Toulouse, France)

P269 **Liver dysfunction in paediatric patients commencing Elexacaftor/tezacaftor /ivacaftor** 14:00 - 14:00

Sarah Murphy (Manchester, United Kingdom)

P270 **Can Elexacaftor/Tezacaftor/Ivacaftor be prescribed in children with cystic fibrosis associated liver disease?** 14:00 - 14:00

Joseph Valamparampil (Birmingham, United Kingdom)

P271 **Proof of concept pilot study to assess the utility of magnetic resonance extra-cellular volume quantification to diagnose advanced liver disease in people with cystic fibrosis** 14:00 - 14:00

Daniel Tewkesbury (Manchester, United Kingdom)

P272 **The effect of CFTR modulators on bilirubin levels in Paediatrics: comparison of bilirubin levels before, and after commencement of Elexacaftor/Tezacaftor/Ivacaftor (ETI)** 14:00 - 14:00

Ashley Cheung (Nottingham, United Kingdom)

P273 **Targeted therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in patients with Gilbert's syndrome** 14:00 - 14:00

Elena Zhekaite (Moscow, Russian Federation)

P274 **Predictors of Cystic Fibrosis Related Liver Disease in Children** 14:00 - 14:00

Birce Sunman (Ankara, Turkey)

P275 **Utility of adding gamma-glutamyl transpeptidase to platelet ratio to cystic fibrosis related liver disease screening** 14:00 - 14:00

Michael Dooney (Blackpool, United Kingdom)

P276	**Elexacaftor-Tezacaftor-Ivacaftor significantlyimprove gastrointestinal symptoms, intestinal ultrasound findings and liver and pancreatic stiffness in people with cystic fibrosis**	14:00 - 14:00
Fabiola Corti (Milan, Italy)		
P277	**The novel CFAbd-Score.kid reveals a significant decline in abdominal symptoms in children with Cystic fibrosis aged 6-<12 years on a new therapy with Elexacaftor/Tezacaftor/Ivacaftor**	14:00 - 14:00
Jochen G. Mainz (Brandenburg an der Havel, Germany)		
P278	**CF Tummy Tracker: A CF-specific patient reported outcome measure for daily gastrointestinal symptom burden**	14:00 - 14:00
Rebecca J. Calthorpe (Nottingham, United Kingdom)		
P279	**Associations between changes in CFAbd-Score, dietary intake and weight following Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy: preliminary analysis**	14:00 - 14:00
Laura Caley (Leeds, United Kingdom)		
P280	**Rapid review of the outcome measures and endpoints used to measure gastrointestinal disease in cystic fibrosis (CARDS-CF study)**	14:00 - 14:00
Jemila Holaman (Nottingham, United Kingdom)		
P281	**Reduced Abdominal Symptoms in people with Cystic Fibrosis receiving Elexacaftor-Tezacaftor-Ivacaftor Treatment: First results Obtained with the Greek version of the CF-Specific CFAbd-Score**	14:00 - 14:00
Elpis Hatziagorou (Thessaloniki, Greece)		
P282	**An evaluation of concurrent FIT and colonoscopies as part of the colorectal screening programme for patients with cystic fibrosis. Is FIT fit for purpose?**	14:00 - 14:00
Aqeem Azam (Manchester, United Kingdom)		
P283	**Exclusion value and comfort level during colonoscopy in a large cohort of people with CF**	14:00 - 14:00
Giulia Spoletini (Leeds, United Kingdom)		
P284	**Patient satisfaction and experience of an intensive bowel cleansing regimen for colonoscopy in a regional adult CF service: Results from an online survey**	14:00 - 14:00
Dee Shimmin (Leeds, United Kingdom)		
P285	**Towards a better understanding of colorectal adenomas and cancer in cystic fibrosis**	14:00 - 14:00
Regina Hofland (Utrecht, Netherlands)		
P286	**Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis. Data from the French observational pediatric study MODUL-CF**	14:00 - 14:00
Laurence Weiss (Strasbourg, France)		
P287	**Influence of Highly Effective Modulator Therapy on CF-related Diabetes: Data from the multicenter diabetes patient registry DPV**	14:00 - 14:00
Thomas Hörtenhuber (Linz, Austria)		
P288	**Examining the impact of utilising continuous glucose monitoring (CGM) as a diagnostic tool for Cystic Fibrosis Related Diabetes (CFRD) on clinical parameters in cystic fibrosis**	14:00 - 14:00
Francine Lewis (Manchester, United Kingdom)		
P289	**Islet Antibody Positivity According to Age and Glucose Tolerance in Cystic Fibrosis: A Systematic Review and Meta-analysis**	14:00 - 14:00
Regina Molnár (Budapest, Hungary)		
P290	**Could Metformin be a viable treatment option for patients with**	14:00 - 14:00

Cystic Fibrosis Diabetes?

Charlotte Dewdney (Edinburgh, United Kingdom)

P291 **Decreased insulin needs and improved glycated hemoglobin after initiation of Elexacaftor-Tezacaftor-Ivacaftor in adults with insulin treated cystic fibrosis related diabetes** 14:00 - 14:00

Espérie Burnet (Paris, France)

P292 **CFTR modulator therapy improves glycemic control in Cystic Fibrosis-Related Diabetes** 14:00 - 14:00

Mihail Basa (Belgrade, Serbia)

P293 **The sweet truth: understanding an unusually high incidence of Cystic Fibrosis-Related Diabetes in our East London paediatric cohort** 14:00 - 14:00

Hannah Corbett (London, United Kingdom)

P294 **To assess the impact structured Cystic Fibrosis Diabetes (CFD) education sessions have on glycaemic control using Hba1c as a measurement in the adult Cystic Fibrosis (CF) unit in Northern Ireland (NI)** 14:00 - 14:00

Emma Molloy (Belfast, United Kingdom)

P295 **Patient satisfaction and experience of having a dedicated CF Diabetes Specialist Nurse within a regional adult CF service: Results from an online survey** 14:00 - 14:00

Benjamin Yusuf (Leeds, United Kingdom)

P296 **Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region** 14:00 - 14:00

Elena Kondratyeva (Moscow, Russian Federation)

P297 **Characteristics of patients with cystic fibrosis–related diabetes (CFRD) in childhood according to the registry of patients with cystic fibrosis of the Russian Federation in 2021** 14:00 - 14:00

Elena Kondratyeva (Moscow, Russian Federation)

P298 **Title**: **Review of Cystic Fibrosis Diabetes service provision at a large paediatric CF centre/paediatric teaching Hospital** 14:00 - 14:00

Katie Harriman (Bristol, United Kingdom)

P299 **The effect of lymecycline on paediatric cystic fibrosis related diabetes in the modulator era** 14:00 - 14:00

Justine Coatman (London, United Kingdom)

P300 **Metabolic complications in an adult Northern Ireland Population with Cystic Fibrosis** 14:00 - 14:00

Veronica Lynch (Belfast, United Kingdom)

P301 **Distal Intestinal Obstruction Syndrome (DIOS) - risk factors and complications. A single centre analysis** 14:00 - 14:00

Patience Eschenhagen (Potsdam, Germany)

P302 **Features of pancreatic insufficiency (PI) in children with cystic fibrosis (CF) of various ethnic groups of the North Caucasus (NC)** 14:00 - 14:00

Ina Sokolov (Moscow, Russian Federation)

P303 **Prevalence and clinical presentation of Inflammatory Bowel Disease (IBD) in a large adult Cystic Fibrosis (CF) Unit** 14:00 - 14:00

Emma Abel (Leeds, United Kingdom)

P304 **Cystic fibrosis patients with fragility rib fracture have more severe clinical parameters and higher mortality rate than those without rib fracture** 14:00 - 14:00

Nathan Wilde (Manchester, United Kingdom)

P305 **Pancreatic function is not a risk factor for cystic fibrosis-related bone disease** 14:00 - 14:00

Miri Dotan (Petach Tikva, Israel)

P306 **Analysis risk factors for the decrease bone mineral density in cystic fibrosis** 14:00 - 14:00

Elena Zhekaite (Moscow, Russian Federation)

P307 **Reduced levels of circulating leptin associate with reduced bone mineral density in cystic fibrosis patients** 14:00 - 14:00

Dina Cosme (Porto, Portugal)

P308 **Bone health in CF: Better as a team** 14:00 - 14:00

Fiona Moore (Glasgow, United Kingdom)

P309 **Evaluating changes in bone health in people with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy** 14:00 - 14:00

Esben Herborg Henriksen (Copenhagen, Denmark)

P310 **Prevalence and predictors of low bone mineral density in adults with cystic fibrosis** 14:00 - 14:00

Laura Kinsey (Manchester, United Kingdom)

P311 **Bone disease in CF: what's the current situation?** 14:00 - 14:00

Mikaela Sze Ann Low (Glasgow, United Kingdom)

P312 **A pilot study of seminal plasma analysis in cystic fibrosis patients compared to a healthy population reveals significant changes in its composition** 14:00 - 14:00

Nela Stastna (Brno, Czech Republic)

P313 **Knowledge and experiences of fertility, contraception and sexual reproductive health among males with cystic fibrosis in the variant specific therapy era** 14:00 - 14:00

Amy Downes (London, United Kingdom)

P314 **Family planning and contraception for females with cystic fibrosis (CF) in the variant specific therapy era** 14:00 - 14:00

Amy Downes (London, United Kingdom)

P315 **Association of cystic fibrosis disease and the menstrual period?** 14:00 - 14:00

Hande Yuce (Ankara, Turkey)

P316 **Increasing numbers of pregnancies due to modulator therapy in cystic fibrosis** 14:00 - 14:00

Guergana Petrova (Sofia, Bulgaria)

P317 **Oro-pharyngeal dysfunction in children with CF – a single centre experience** 14:00 - 14:00

Esther Wright (Belfast, United Kingdom)

P318 **Abdominal symptoms after longer term use of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis** 14:00 - 14:00

Lindsey Gillgrass (Leeds, United Kingdom)

P319 **The impact of a Whole Foods Dietary Intervention on Gastrointestinal (GI) symptoms, Inflammation, and Fecal Microbiota in Pediatric Patients with Cystic Fibrosis: A pilot study** 14:00 - 14:00

Nicole Green (Seattle, United States)

P320 **Impact of extended elexacaftor/tezacaftor/ivacaftor therapy on the gut microbiome in cystic fibrosis** 14:00 - 14:00

Ryan Marsh (Newcastle upon Tyne, United Kingdom)

P321 ***Lactiplantibacillus plantarum* supplementation reshapes gut microbiota and metabolite production in gut dysbiosis associated with cystic fibrosis (CFRGD): a dynamic in vitro study.** 14:00 - 14:00

Andrea Asensio-Grau (Valencia, Spain)

P322 **A quality improvement project to assess safety of reducing pancreatic enzyme replacement therapy in children with Cystic Fibrosis who have restored pancreatic function as a result of CFTR modulators** 14:00 - 14:00

Hannah Harding (Leicester, United Kingdom)

P323 **Gastrointestinal health through self-reported assessment in children with cystic fibrosis** 14:00 - 14:00

Ellen K-N (Gothenburg, Sweden)

P324 **Changes to the dietetic landscape in a UK adult Cystic Fibrosis centre following the introduction of triple CFTR modulator therapy and continuous glucose monitoring to screen for CF Diabetes** 14:00 - 14:00

Carolyn Bradshaw (Frimley, United Kingdom)

P325 **An audit of an adult CF centre bone health screening programme post COVID-19** 14:00 - 14:00

Katie Marsden (Birmingham, United Kingdom)

P327 **Dietitians experiences of gastrostomy tube removal among people with cystic fibrosis on highly effective modulator therapy** 14:00 - 14:00

Grace Miller (Dublin, Ireland)

P328 **Characterisation of enteral nutrition dependence in people with cystic fibrosis in an era of modulator therapy** 14:00 - 14:00

Eimear McCausland (Dublin, Ireland)

P329 **Assessment of diet quality in Irish adults with Cystic Fibrosis using validated diet quality index tools: Healthy Eating Index 2020 (HEI-2020) & Diet Quality Index – International (DQI-I).** 14:00 - 14:00

Clodagh Landers (Co.Dublin, Ireland)

P330 **Navigating the unknown : an international survey of current dietetic practices for overweight and obesity in people with cystic fibrosis** 14:00 - 14:00

Joanna Snowball (Oxford, United Kingdom)

P331 **Salt intake in children with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI)** 14:00 - 14:00

Helene Attew (Montpellier, France)

P332 **Does Cyproheptadine Actually Promote Weight Gain in Children with Cystic Fibrosis?** 14:00 - 14:00

Birce Sunman (Ankara, Turkey)

P333 **A Quality Improvement Project to pilot the Eating Attitudes and Behaviours tool in Manchester Adult Cystic Fibrosis Centre** 14:00 - 14:00

Laura Kinsey (Manchester, United Kingdom)

P334 **SCREENING FOR FOOD INSECURITY IN INDIVIDUALS WITH CYSTIC FIBROSIS** 14:00 - 14:00

Damla Kocaman (Istanbul, Turkey)

P335 **Which foods should we recommend in complementary feeding?** 14:00 - 14:00

Joaquim Calvo-Lerma (València, Spain)

P336 **In an increasingly overweight population, are those with Cystic Fibrosis (CF) able to correctly identify macronutrients in their diet?** 14:00 - 14:00

Jennifer Still (ABERDEEN, United Kingdom)

P337 **Living in a post-pandemic world amidst a cost of living crisis - a** 14:00 - 14:00

service development pilot to explore changing social needs and tailor support for adults with Cystic Fibrosis

Rebecca Fallon (Manchester, United Kingdom)

P338 **Analysis of the nutritional status of children with cystic fibrosis. Experiences with the use of oral nutritional supplements** 14:00 - 14:00

Vera Zarubina (Moscow, Russian Federation)

P339 **Maintenance of nutritional parameters improvements over two years of Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment according to severity of Cystic Fibrosis (CF) pulmonary disease** 14:00 - 14:00

Cecilia Brignole (Verona, Italy)

P340 **Despite an unchanged energy intake, both pediatric and adult cystic fibrosis (CF) patients experienced improvement in their body mass index (BMI) under ETI modulator therapy** 14:00 - 14:00

Marie Mittaine (Toulouse, France)

P341 **Real-world impact of 24-month LUM/IVA therapy on BMI, body composition, and fecal elastase levels in pediatric cystic fibrosis: A Comprehensive Cohort Analysis** 14:00 - 14:00

Marcell Imrei (Budapest, Hungary)

P342 **Hand Grip Strength, Skeletal Muscle Mass, and Physical Activity in Children with Cystic Fibrosis: Impact of CFTR modulator therapy** 14:00 - 14:00

Beatrix Riba (Budapest, Hungary)

P343 **Two years of elexacaftor/tezacaftor/ivacaftor has consistent effects on body composition in homozygous and heterozygous F50del patients with cystic fibrosis** 14:00 - 14:00

Andrea Vukić Dugac (Zagreb, Croatia)

P344 **Weight and wellbeing on elexacaftor/tezacaftor/ivacaftor** 14:00 - 14:00

Leah Harneshaug (Newcastle upon Tyne, United Kingdom)

P345 **BMI (Z-scores) in children with cystic fibrosis improved despite comparable energy and nutritional intake following the introduction of elexacaftor/tezacaftor/ivacaftor therapy** 14:00 - 14:00

Anija Orel (Ljubljana, Slovenia)

P346 **Longitudinal growth patterns; are children with CF still at risk for deprived final height?** 14:00 - 14:00

Gizem Tamer (Utrecht, Netherlands)

P347 **Do we really know what a healthy BMI looks like? : a single centre service evaluation of body composition data using bioelectrical impedance.** 14:00 - 14:00

Joanna Snowball (Oxford, United Kingdom)

P348 **Nutritional challenges in the era of Cystic Fibrosis Transmembrane Regulator modulators: can we still trust the Body Mass Index?** 14:00 - 14:00

Veronica Zamponi (Ancona, Italy)

P349 **BMI trends in adults with cystic fibrosis between 2018-2023** 14:00 - 14:00

Caroline Anne Holland (Blackpool, United Kingdom)

P350 **Dual x-ray absorptiometry body composition assessment in children and adolescents with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor** 14:00 - 14:00

Uros Krivec (Ljubljana, Slovenia)

P351 **The Impact of CFTR Modulators on Nutritional Status in people with Cystic Fibrosis** 14:00 - 14:00

Elpis Hatziagorou (Thessaloniki, Greece)

P352 **The impact of Kaftrio® on growth and body composition in children** 14:00 - 14:00

with cystic fibrosis: new challenges for the dietitian

Floor Wynants (Leuven, Belgium)

P353 **Changes in nutritional status and body composition after one year of Elexacaftor/Ivacaftor/Tezacaftor treatment – exploring influencing factors** 14:00 - 14:00

Monika Mielus (Warsaw, Poland)

P354 **An evaluation of weight loss in patients undergoing eradication therapy for Pseudomonas Aeruginosa** 14:00 - 14:00

Elizabeth Sheppard (Manchester, United Kingdom)

P355 **Long-Term Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy on Weight Gain and Body Composition in Adult Cystic Fibrosis Patients: A Retrospective Analysis** 14:00 - 14:00

Zrinka Šmuljić (Zagreb, Croatia)

P356 **The impact of Kaftrio® on body mass index and body composition in people with cystic fibrosis** 14:00 - 14:00

Floor Wynants (Leuven, Belgium)

P357 **Effect of ELEXACAFTOR-TEZACAFTOR-IVACAFTOR on metabolic parameters and body weight in patients with cystic fibrosis: a five case series with one-year follow-up** 14:00 - 14:00

Matteo De Marchis (Catanzaro, Italy)

P358 **Effect of triple modulator therapy with elexacaftor/tezacaftor/ivacaftor on nutritional status in a series of cystic fibrosis patients** 14:00 - 14:00

Andrijana Andreevska Stepanovska (Skopje, North Macedonia)

P359 **The Impact of Kaftrio on the weight trajectories of children and adolescents and predictive factors** 14:00 - 14:00

Steve Jones (Sheffield, United Kingdom)

P360 **CFTR Modulator Therapy with Elexacaftor/Tezacaftor/Ivacaftor Increases Plasma Concentration of Fat-Soluble Carotenoids in Patients with Cystic Fibrosis** 14:00 - 14:00

Jaehi Chung (Heidelberg, Germany)

P361 **Effect of CFTR modulator therapy on circulating levels of fat-soluble vitamins in Cystic Fibrosis patients – a single centre experience** 14:00 - 14:00

Agata Ladić (Zagreb, Croatia)

P362 **Vitamin A deficiency in the West of Scotland Adult CF Centre** 14:00 - 14:00

Fiona Moore (Glasgow, United Kingdom)

P363 **A retrospective review of fat-soluble vitamins A, D and E levels and vitamin supplementation in a Cystic Fibrosis (CF) maternal health population** 14:00 - 14:00

Ingrid Brockie (London, United Kingdom)

P364 **Trends in fat soluble vitamin levels in children with Cystic fibrosis on Kaftrio** 14:00 - 14:00

Fern Kimber (Nottingham, United Kingdom)

P365 **Vitamin D quality improvement implementation: one year on** 14:00 - 14:00

Jessica Gadsby (Leicester, United Kingdom)

P366 **Fat-soluble vitamin status and treatment satisfaction in young children using a Cystic Fibrosis (CF) specific multivitamin** 14:00 - 14:00

Anne Munck (Paris, France)

P367 **A retrospective evaluation of vitamin D levels in children with CF on Elexacaftor/Tezacaftor/Ivacaftor treatment** 14:00 - 14:00

Caroline Powell (Cardiff, United Kingdom)

P368 **Alterations in fat soluble vitamin levels in adults with cystic fibrosis** 14:00 - 14:00
Alicja Ochota (Liverpool, United Kingdom)

P369 **A rapid review on the impact of CFTR modulators on fat-soluble vitamin levels in people with Cystic fibrosis** 14:00 - 14:00
Fern Kimber (Nottingham, United Kingdom)

P370 **Night blindness in a Cystic Fibrosis (CF) patient; can we correct suboptimal vitamin A orally?** 14:00 - 14:00
Jennifer Still (ABERDEEN, United Kingdom)

P371 **The impact of Elexacaftor/Tezacaftor/Ivacaftor on Mental Health in Young Children with Cystic Fibrosis** 14:00 - 14:00
Saskia Gruber (Vienna, Austria)

P372 **REVEAL; PaRents pErspectiVEs of kAftrio in chiLdren aged 2-5** 14:00 - 14:00
Sioned Davies (Liverpool, United Kingdom)

P373 **Impact of Elexacaftor/Tezacaftor/Ivacaftor on quality of life in children with cystic fibrosis** 14:00 - 14:00
Isabelle Rochat (Lausanne, Switzerland)

P374 **Effect of CFTR-modulators on Cystic Fibrosis related school absenteeism in children attending primary school** 14:00 - 14:00
Karin Risager Jakobsen (Aarhus N, Denmark)

P375 **Psychological well-being of adolescents with cystic fibrosis after 1 year on triple CFTR modulators** 14:00 - 14:00
Urszula Borawska - Kowalczyk (Warsaw, Poland)

P376 **The occurence of side effects after administration of ETI in Czech CF adults** 14:00 - 14:00
Pavla Hodková (Praha 5, Czech Republic)

P377 **Following the introduction of Kaftrio®: a psychosocial perspective** 14:00 - 14:00
Eleonora Falk (Stockholm, Sweden)

P378 **COMPARISON OF ANXIETY AND DEPRESSION LEVELS IN CYSTIC FIBROSIS PATIENTS WITH AND WITHOUT MODULATORY THERAPY** 14:00 - 14:00
Burcu Uzunoglu (Istanbul, Turkey)

P379 **“Now I have a future”: Adult perspectives and experiences of health status and adherence post CFTR modulator therapy** 14:00 - 14:00
Nicola Shaw (Leeds, United Kingdom)

P380 **Health care professionals' perspectives on the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the clinical care of adults with CF within the CFHealthHub Learning Health System: preliminary data** 14:00 - 14:00
Robert D Sandler (Sheffield, United Kingdom)

P381 **The impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on ante-natal and post-natal experience of women with Cystic Fibrosis** 14:00 - 14:00
Ruth Padmore (Edinburgh, United Kingdom)

P382 **An ethical framework to ensure elexacaftor/tezacaftor/ivacaftor access for pediatric patients and families who are unable to follow treatment regimen** 14:00 - 14:00
Mark Chilvers (Vancouver, Canada)

P383 **Kaftrio and the Octogenarian: a case study** 14:00 - 14:00
Genna Wood (Aberdeen City, United Kingdom)

P384 **Impact of elexacaftor/tezacaftor/ivacaftor modulating therapy on multiple aspects of quality of life in cystic fibrosis patients: A case series** 14:00 - 14:00

Andrijana Andreevska Stepanovska (Skopje, North Macedonia)

P385 **Voices of Transformation: Navigating Life with 'New Cystic Fibrosis' - A Qualitative Exploration of ETI Therapy Perspectives** 14:00 - 14:00

Malin Heiden (Copenhagen, Denmark)

P386 **The Dutch Gastrointestinal Symptom Tracker for People with Cystic Fibrosis: Associations with anxiety, depression and health-related quality of life** 14:00 - 14:00

Marieke Verkleij (Amsterdam, Netherlands)

P387 **Strengths and difficulties scores in children with Cystic Fibrosis enrolled in the CLIMB-CF study** 14:00 - 14:00

Claire Edmondson (London, United Kingdom)

P388 **Mental health scores in adults with cystic fibrosis are not strongly associated with clinical outcomes** 14:00 - 14:00

Marit Vold Heddan (Oslo, Norway)

P389 **Patients without F508del mutation at Stockholm CF Centre experience living with cystic fibrosis burdensome and show signs of anxiety and/or depression to a higher degree than those with F508del** 14:00 - 14:00

Carolina Laine (Stockholm, Sweden)

P390 **Cystic Fibrosis, autism and protracted course of allergic bronchopulmonary aspergillosis: adding fuel to the fire** 14:00 - 14:00

Pauline Singleton (Middlesbrough, United Kingdom)

P391 **A national survey to inform feasibility of adding mental health variables to the Cystic Fibrosis Foundation Patient Registry** 14:00 - 14:00

Anna M. Georgiopoulos (Boston, United States)

P392 **My view counts too! A perspective centered on children aged between 2 and 5 years of quality of life with cystic fibrisis** 14:00 - 14:00

Simona Caldani (Paris, France)

P393 **‘Giving me the reins’: assessing quality of life from the patients’ point of view** 14:00 - 14:00

Simona Caldani (Paris, France)

P394 **Implementation of CF-CBT in US and Canadian CF centers: adoption, effectiveness and reach in phase one** 14:00 - 14:00

Anna M. Georgiopoulos (Boston, United States)

P395 **Evaluation of a tree of life group in a paediatric cystic fibrosis service** 14:00 - 14:00

Adele de Gray Towell (Leicester, United Kingdom)

P396 **Evaluating the effectiveness of mindful eating practices (CFMEPs) in supporting identified goals of self-regulation of eating behaviours in an adult cohort of people with Cystic Fibrosis** 14:00 - 14:00

Helen Egan (Birmingham, United Kingdom)

P397 **Work Forwards: a new programme of employment support for people affected by cystic fibrosis** 14:00 - 14:00

Becky Kilgariff (London, United Kingdom)

P398 **Indelible – People living with cystic fibrosis and their tattoos** 14:00 - 14:00

Joke Snick (Gent, Belgium)

P399 **Child life interventions: Caring for the pediatric Cystic Fibrosis population in the outpatient setting** 14:00 - 14:00

Kelsey Gregorio (Ann Arbor, United States)

P400 **"It's good to talk" The development and acceptability of online group support sessions for adults with CF in a large adult CF centre in the UK** 14:00 - 14:00

Jacqui Wainwright (Birmingham, United Kingdom)

P401 **Making connections: the implementation of an age specific youth group across Southampton Children's Hospital's Cystic Fibrosis (CF) service** 14:00 - 14:00

Sophie Sinnott (Southampton, United Kingdom)

P402 **Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study** 14:00 - 14:00

Laura Brown (Bath, United Kingdom)

P403 **Communication and management of Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): what have families experienced, and how can they be better supported by healthcare professionals?** 14:00 - 14:00

Faye Johnson (Manchester, United Kingdom)

P404 **Embedding Motivational Interviewing Techniques into CF MDT practice** 14:00 - 14:00

Aimée Stimpson (Cardiff, United Kingdom)

P405 **Using the 'Patients Know Best' Digital Patient Portal to Improve and Coordinate Communication Across a UK Cystic Fibrosis Healthcare Network** 14:00 - 14:00

Erin Hodgetts (Stoke on Trent, United Kingdom)

P406 **Producing website content on vaping for people with cystic fibrosis** 14:00 - 14:00

Jessica Denning (London, United Kingdom)

P407 **Is it possible to increase parental knowledge about cystic fibrosis through education?** 14:00 - 14:00

mine kalyoncu (istanbul, Turkey)

P408 **The Halo effect in Cystic Fibrosis: when educated patients in turn educate their family carers** 14:00 - 14:00

Raphael Chiron (Montpellier, France)

P409 **Increased Knowledge Levels of Cystic Fibrosis Patients Following İmplementation of a Standard and Modified CF R.I.S.E Programme in a Limited Resource Country** 14:00 - 14:00

Merve Selçuk Balcı (Istanbul, Turkey)

P410 **Patient Satisfaction after Transition to Adult CF Clinic** 14:00 - 14:00

Moshe Heching (Petach Tikva, Israel)

P411 **Benchmark of transitional care from paediatric to adult cystic fibrosis provision, audited against National Institute for Health and Care Excellence (2016) best practice standards** 14:00 - 14:00

Steven Stirk (Cardiff, United Kingdom)

P412 ***"Should I stay or should I go now?"* (Transitioning to CF Adult Care)** 14:00 - 14:00

Mel Shanley (Dublin, Ireland)

P413 **Sexual and reproductive health in adult patients with cystic fibrosis - a scoping multidisciplinary questionnaire to guide future cystic fibrosis care** 14:00 - 14:00

Wendy Foo (Manchester, United Kingdom)

P414 **Providing advice and information to women with cystic fibrosis on** 14:00 - 14:00

their reproductive choices

Susan Parker (Newcastle upon Tyne, United Kingdom)

P415 **Impact of parenthood on cystic fibrosis (CF) self-care and service implications** 14:00 - 14:00

Amy Downes (London, United Kingdom)

P416 **Routes to parenthood taken by people with cystic fibrosis (pwCF) in the variant specific (VST) era** 14:00 - 14:00

Amy Downes (London, United Kingdom)

P417 **Cystic fibrosis patients' experience of entering motherhood following the introduction of highly effective modulator therapy: an interpretative phenomenological analysis of psychosocial factors** 14:00 - 14:00

Stephanie Birney (Glasgow, United Kingdom)

P418 **Tell me your story: conducting research interviews with older people with cystic fibrosis** 14:00 - 14:00

Janet E. Mitchell (Manchester, United Kingdom)

P419 **Adding insult to injury: the experience of ageing with cystic fibrosis and developing new health conditions** 14:00 - 14:00

Janet E Mitchell (Manchester, United Kingdom)

P420 **A new era for CF Nurse Specialists: Rebuilding the Cystic Fibrosis Nursing Association (CFNA) post COVID-19 pandemic** 14:00 - 14:00

Caroline Whitton (Plymouth, United Kingdom)

P421 **The development of a pathway to gastrostomy removal in children with cystic fibrosis** 14:00 - 14:00

Ruth Hollin (South Brisbane, Australia)

P422 **The reduction of totally implanted venous access devices in our paediatric population as health outcomes improve.** 14:00 - 14:00

Louise Wooldridge (Birmingham, United Kingdom)

P423 ***Title:*** **Nebuliser Equipment: How clean is yours?** 14:00 - 14:00

Catherine 0'Grady (Dublin, Ireland)

P424 **Totally implantable venous access devices (TIVADs) flushing intervals: Where are we?** 14:00 - 14:00

Bushra Nahid (Stoke on Trent, United Kingdom)

P425 **0.9% saline is as effective as heparinised saline at preventing occlusion of totally implantable central venous catheters (TIVADs): a systematic review** 14:00 - 14:00

Caroline Whitton (Plymouth, United Kingdom)

P426 **Patterns of telephone inquiries to the cystic fibrosis nursing team at a large tertiary hospital in North West United Kingdom** 14:00 - 14:00

Anirban Maitra (Manchester, United Kingdom)

P427 **Medicines optimisation: Using adherence to support supply** 14:00 - 14:00

Rianna White (Nottingham, United Kingdom)

P428 **Experiences of paediatric cystic fibrosis care in the UK** 14:00 - 14:00

Jana Witt (London, United Kingdom)

P429 **The role of Cystic Fibrosis Nurse Specialist (CFNS) in the Annual Review (AR) process for adults living with CF in the post-modulator era: A single centre experience** 14:00 - 14:00

Jennifer Daniels (Liverpool, United Kingdom)

P430 **Impact analysis of an updated Did Not Attend policy on long term clinic attendance** 14:00 - 14:00

Michael Dooney (Blackpool, United Kingdom)

P431 **The key role of the Cystic Fibrosis Clinical Nurse Specialist 30 years on** 14:00 - 14:00

Lesley Blaikie (Inverness, United Kingdom)

P432 **Working in partnership to support new parents with CF - in Glasgow!** 14:00 - 14:00

Becky Kilgariff (London, United Kingdom)

P433 **Psychology Supervision for Diabetes Nurse Specialists: A collaborative psychologically informed approach to the management of engagement and adherence issues for individuals with CF Related Diabetes** 14:00 - 14:00

Rachael Faulkner (Manchester, United Kingdom)

P434 **Initial reflections on the clinical utility of ADAPT-CF UK version for identifying CF care needs at paediatric annual review** 14:00 - 14:00

Cathy Warde (Brighton, United Kingdom)

P435 **Recognising and Responding to Risk & Need: A Social Work Perspective. A thematic analysis exploring professional confidence, knowledge, and responsibility** 14:00 - 14:00

Katie Smith (Southampton, United Kingdom)

P436 **Hope CF, transforming healthcare workflow and patient engagement in people with CF** 14:00 - 14:00

Frida Olofsson (Gothenburg, Sweden)

P437 **Supporting mental health for people with CF in Jordan through quality improvement partnerships with US CF centers and nonprofit organizations** 14:00 - 14:00

Carolyn Snell (Boston, United States)

P438 **Cystic Fibrosis Care in Lebanon** 14:00 - 14:00

Paul-Henri Torbey (Beirut, Lebanon)

P439 **Partnership of Slovakia, Ukraine and France created a new CF centre in Ukraine in Ivano-Frankivsk region by Slovak-Ukraine cross-border project** 14:00 - 14:00

Katarina Stepankova (Kosice, Slovakia)

P440 **Understanding the acceptability of the increased use of telehealth in cystic fibrosis care** 14:00 - 14:00

Michael Doumit (Macquarie Park, Australia)

P441 **Virtual wards for providing hospital-at-home care for adults with cystic fibrosis** 14:00 - 14:00

Laura Blanch (Newcastle upon Tyne, United Kingdom)

P442 **Do video conference calls contribute to increased gender equity among caregivers of children with a chronic disease?** 14:00 - 14:00

Viktoria Mellqvist (Gothenburg, Sweden)

P443 **Challenges of app-supported home monitoring for people with CF and the CF care team** 14:00 - 14:00

Anna-Lena Strehlow (Bonn, Germany)

P444 **A time of change: evolving workload in cystic fibrosis** 14:00 - 14:00

Jana Witt (London, United Kingdom)

P445 **A journey to achieve global harmonisation for physiotherapy outcome measures** 14:00 - 14:00

Lisa Morrison (Glasgow, United Kingdom)

P446 **Virtual physiotherapy annual reviews: Remotely useful?** 14:00 - 14:00

Emily Scott (Liverpool, United Kingdom)

P447	**Independent Induced Sputum Service Development at the Blackpool Adult Cystic Fibrosis Service**	14:00 - 14:00
Natasha Pickering (Blackpool, United Kingdom)		
P448	**An audit to compare bacteria growth in standard routine cough swabs done at annual review compared to an Induced Sputum in children with Cystic Fibrosis**	14:00 - 14:00
Hannah Day (Sheffield, United Kingdom)		
P449	**A new way of approaching sputum induction in the era of modulator therapy in paediatric Cystic Fibrosis**	14:00 - 14:00
Carolyn Aitken-Arbuckle (Edinburgh, United Kingdom)		
P450	**Sputum Induction- A Quality Improvement Initiative**	14:00 - 14:00
Ciara O' Connor (Dublin, Ireland)		
P451	**The utility of induced sputum sampling vs cough swab for detecting pathogens in children with cystic fibrosis**	14:00 - 14:00
Joanne Lawrie (Glasgow, United Kingdom)		
P452	**Effects of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Mid-Upper Arm Circumference (MUAC) and Muscle Strength in Pediatric Cystic Fibrosis Patients: A Single Center Retrospective Analysis**	14:00 - 14:00
Carola Y Timmer (Groningen, Netherlands)		
P453	**Correlation of the upper and lower extremity muscle strength with performance tests in patients with cystic fibrosis**	14:00 - 14:00
Ozge Kenis-Coskun (İstanbul, Turkey)		
P454	**Body composition and peripheral muscle function in people with cystic fibrosis established on Elexacaftor/Tezacaftor/Ivacaftor**	14:00 - 14:00
Lauren Clayton (Portsmouth, United Kingdom)		
P455	**Experiences of participants and staff involved in the Exercise as an Airway Clearance Technique in people with Cystic Fibrosis pilot feasibility trial: preliminary findings from a qualitative study**	14:00 - 14:00
Emily Taylor (Edinburgh, United Kingdom)		
P456	**Review of airway clearance techniques and compliance following the initiation of Kaftrio in a single centre paediatric CF population**	14:00 - 14:00
Naomi Dayman (Leicester, United Kingdom)		
P457	**Kids ACTing Up: Airway clearance therapy adherence and mucolytic use after starting elexacaftor/tezacaftor/ivacaftor**	14:00 - 14:00
Nicole Lee Son (Vancouver, Canada)		
P458	**Let's Talk About PEP- Baby: Outcomes of a UK survey, investigating infant Positive Expiratory Pressure (iPEP) practice**	14:00 - 14:00
Emma Dixon (London, United Kingdom)		
P459	**Please can you bring your physio equipment to clinic? – does sending a text message help with review of airway clearance technique**	14:00 - 14:00
Christine Blackburn (Leeds, United Kingdom)		
P460	**Assessing the exercise capacity of adolescents with cystic fibrosis in the post Elexacaftor, Tezacaftor, Ivacaftor era, via cardiopulmonary exercise test**	14:00 - 14:00
Thomas Larcombe (Southampton, United Kingdom)		
P461	**Agreement between peak power equations during cardiopulmonary exercise testing in cystic fibrosis**	14:00 - 14:00
Thomas Kent (Exeter, United Kingdom)		
P462	**Applicability of A-STEP performance test in patients diagnosed with Cystic Fibrosis in Turkish Population**	14:00 - 14:00

Ozge Kenis-Coskun (İstanbul, Turkey)

P463 **An analysis of 1 min sit-to-stand outcomes compared to reference values** 14:00 - 14:00

Kowin Sangtani (Manchester, United Kingdom)

P464 **A-STEP maximal exercise test: Argentinian experience of efficacy for evaluation of exercise capacity in pediatrics and adolescent's patients with cystic fibrosis** 14:00 - 14:00

Graciana D'Agostino (La Plata, Argentina)

P465 **Exercise participation amount correlates with overall wellness as measured by the Alfred Wellness Score (AWESCORE) in adults with cystic fibrosis** 14:00 - 14:00

Brenda Button (Melbourne, Australia)

P466 **Yoga in children with Cystic Fibrosis: complementary therapy alternative to the yoga practice in the presence** 14:00 - 14:00

Arianna Peruzzi (Ancona, Italy)

P467 **The impact of elexacaftor/tezacaftor/ivacaftor on physical activity and physiotherapy adherence among people with Cystic Fibrosis – a single center experience** 14:00 - 14:00

Elpis Hatziagorou (Thessaloniki, Greece)

P468 **Exploring parents' perceptions of school-based physical activity for children with cystic fibrosis in helping to maintain health and reduce the burden of care** 14:00 - 14:00

Emma Powell (Birmingham, UK, United Kingdom)

P469 **A service evaluation of a virtual Pilates course in adults with cystic fibrosis** 14:00 - 14:00

Elizabeth Banks (Camberley, United Kingdom)

P470 **Impact of collaboration with local gym to facilitate access to exercise facilities** 14:00 - 14:00

Christine Blackburn (Leeds, United Kingdom)

P471 **The relationship between parent and child physical activity levels in Cystic Fibrosis** 14:00 - 14:00

Tom Meredith (Southampton, United Kingdom)

P472 **Exercise education for professionals in cystic fibrosis: An international journal club** 14:00 - 14:00

Owen William Tomlinson (Exeter, United Kingdom)

P473 **Physical literacy in young adults with Cystic Fibrosis** 14:00 - 14:00

Marcella Burghard (Utrecht, Netherlands)

P474 **A simple, low-cost positive expiratory pressure device has good satisfaction and improves ease of expectoration in people with cystic fibrosis in Brazil** 14:00 - 14:00

Jamie Wood (New York, United States)

P475 **A retrospective review of fluoroquinolone associated tendinopathy among cystic fibrosis patients in a national cystic fibrosis centre** 14:00 - 14:00

Aoibheann Leeney (Dublin, Ireland)

P476 **Downloading…'A Service Review of Nebulised Medication Compliance in the Highly Effective Modulator Therapy Era'** 14:00 - 14:00

Harriet Wood (Liverpool, United Kingdom)

P477 **How the use of nocturnal non-invasive ventilation and oxygen therapy changes in patients with cystic fibrosis using Elexacaftor/Tezacaftor/Ivacaftor** 14:00 - 14:00

Letizia Luciani (Torrette di Ancona, Italy)

P478 **Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline** 14:00 - 14:00

Lue Drasbaek Philipsen (Copenhagen, Denmark)

P479 **Independent prescribing in Cystic Fibrosis, A survey of UK Physiotherapy practice** 14:00 - 14:00

Zoe Johnstone (Edinburgh, United Kingdom)

P480 **Transition service: a review of UK practice** 14:00 - 14:00

Rachael Bass (Newcastle Upon Tyne, United Kingdom)

Workshop
15:00 - 16:30 R1

WS10 - Evaluating the outcomes of novel CFTR-targeted therapies

Batsheva Kerem (Mevaseret, Israel)

WS10.01 **Administration of lentiviral vector doses achieving high transduction efficiency is well tolerated in mice** 15:00 - 15:15

Uta Griesenbach (London, United Kingdom)

WS10.02 **Mind the gap! Impact of GLI Global and GLI 2012 spirometry reference equations on clinical trial eligibility: the London experience** 15:15 - 15:30

Idan Bokobza (London, United Kingdom)

WS10.03 **Inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: A Phase 1 Study** 15:30 - 15:45

David E Geller (San Diego, United States)

WS10.04 **CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities** 15:45 - 16:00

Jennifer L. Taylor-Cousar (Denver, United States)

WS10.05 **Subject selection plan for CHOICES clinical trial aiming to assess efficacy of new CFTR modulators and to validate the intestinal organoid model** 16:00 - 16:15

Marlies Destoop (Utrecht, Netherlands)

WS10.06 **Real-time breath metabolomics to monitor the response to CFTR modulators in adults with cystic fibrosis** 16:15 - 16:30

Emmanuelle Bardin (Paris, France)

Workshop
15:00 - 16:30 R2

WS11 - Diagnosing cystic fibrosis and screening for complications

Elke De Wachter (Brussels, Belgium)

WS11.01 **The use of salivary chloride levels as a screening tool to identify children with Cystic Fibrosis** 15:00 - 15:15

Supriya Suresh Shinde (Southampton, United Kingdom)

WS11.02 **The limitations of sweat chloride testing in adults: results from a national Difficult Cystic Fibrosis (CF) Diagnosis service** 15:15 - 15:30

Rachel Robinson (London, United Kingdom)

WS11.03 **Early cystic fibrosis lung disease in the TRACK-CF cohort: What longitudinal Multiple-Breath Washout and Chest Magnetic Resonance Imaging teach us** 15:30 - 15:45

Eva Steinke (Berlin, Germany)

WS11.04 **Evaluation of lung computed tomography screening of patients with cystic fibrosis according to a modified Lung-RADS score** 15:45 - 16:00

Mary Salvatore (New York, United States)

WS11.05 **Scanning the landscape: ECFS Clinical Trial Network: CT Imaging Monitoring Strategies:** 16:00 - 16:15

Kate Hill (Belfast, United Kingdom)

WS11.06 **(How) should we follow up infants exposed to CFTR modulators in utero? Major variation between centres in the UK** 16:15 - 16:30

Idan Bokobza (London, United Kingdom)

Workshop
15:00 - 16:30 R3

WS12 - Innovations in nutrition and dietetics for cystic fibrosis management

Fiona Moore (Glasgow, United Kingdom)
Monika Mielus (Warsaw, Poland)

WS12.01 **How dietary fat is digested and absorbed determines nutritional status and gut microbiota in children with CF** 15:00 - 15:10

Joaquim Calvo-Lerma (València, Spain)

WS12.02 **Appetite stimulation, eating behaviors, and growth in children with cystic fibrosis aged 2-5 years: FIRST Study, Phase II** 15:10 - 15:20

Catherine McDonald (Salt Lake City, United States)

WS12.03 **Elexacaftor/tezacaftor/ivacaftor (ETI) therapy increases fat-soluble vitamin levels in children with Cystic Fibrosis** 15:20 - 15:30

Maryam Sahibqran (Glasgow, United Kingdom)

WS12.04 **Occurrence of vitamin A hypervitaminosis in children with cystic fibrosis after elexacaftor/tezacaftor/ivacaftor therapy initiation** 15:30 - 15:40

Anja Praprotnik Novak (Ljubljana, Slovenia)

WS12.05 **Effect of high intensity interval training versus moderate intensity continuous training on appetite control and body composition in adults with Cystic Fibrosis – a randomized controlled study** 15:40 - 15:50

Jana Koop (Kiel, Germany)

WS12.06 **Elexacaftor tezacaftor ivacaftor improves iron status and is associated with correction of systemic inflammation and improvement of nutritional status: a one-year prospective multicentre study** 15:50 - 16:00

Quitterie Reynaud (Lyon, France)

Workshop
15:00 - 16:30 R4

WS13 - Inflammation and infection discovery science

Cliff Taggart (Belfast, United Kingdom)

WS13.01 **Proteomic analysis of nasal lavage fluid samples in people with cystic fibrosis after one year of treatment with Elexacaftor/Ivacaftor/Tezacaftor – the RECOVER Study** 15:00 - 15:10

Samuel Nolan (Belfast, United Kingdom)

WS13.02 **Bronchoalveolar lavage metabolites outperform those in matched sputum for monitoring lung damage and inflammation in toddlers with cystic fibrosis** 15:10 - 15:20

Joshua Chandler (Atlanta, United States)

WS13.03 **Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del** 15:20 - 15:30

Daniel Peckham (Leeds, United Kingdom)

WS13.04 **Multimodal analysis of systemic inflammatory response to Elexacaftor/tezacaftor/ivacaftor therapy** 15:30 - 15:40

Robert Lord (Manchester, United Kingdom)

WS13.05 **Intrapulmonary treatment with *Ligilactobacillus murinus* reduces airway inflammation and mucus plugging in neonatal βENaC-transgenic mice with cystic fibrosis-like lung disease** 15:40 - 15:50

Laura Schaupp (Berlin, Germany)

WS13.06 **Granulocyte-macrophage colony stimulating factor is essential for effective macrophage killing of nontuberculous mycobacteria** 15:50 - 16:00

Katie Hisert (Denver, United States)

Workshop
15:00 - 16:30 R5

WS14 - Understanding the role of CFTR and the effects of CFTR-modulating drugs on tissue function: from lungs to bones and beyond

Kavisha Arora (Los Angeles, United States)

WS14.01 **Elexacaftor/Tezacaftor/Ivacaftor treatment partially normalizes osteoclasts' bone resorption activity in cystic fibrosis-related bone disease** 15:00 - 15:15

Johan Sergheraert (Reims, France)

WS14.02 **TEZACAFTOR IS A DIRECT INHIBITOR OF SPHINGOLIPID DELTA-4 DESATURASE ENZYME (DEGS)** 15:15 - 15:30

Andrea Armirotti (Genoa, Italy)

WS14.03 **May CFTR inhibition-related lipid accumulation in skeletal stem cells lead to Cystic Fibrosis-related Bone Disease?** 15:30 - 15:45

Laurine Hamon (Reims, France)

WS14.04 **Combined therapeutic strategies to favor the repair and regeneration of airway epithelium in cystic fibrosis** 15:45 - 16:00

Emmanuelle Brochiero (Montreal, Canada)

WS14.05 **Impact of KvLQT1 K^+ channel modulation on repair and regeneration processes of the airway epithelium in cystic fibrosis** 16:00 - 16:15

Damien Adam (Montréal, Canada)

WS14.06 **Role of CFTR in Airway Epithelial Differentiation and Regeneration: Studies from Novel Human Basal Cell Lines** 16:15 - 16:30

Margarida Amaral (Lisboa, Portugal)

Workshop
17:00 - 18:30 R1

WS15 - Expanding the knowledge on CFTR modulators

Silke van Koningsbruggen-Rietschel (Cologne, Germany)

WS15.01 **Maternal and fetal outcomes in the era of CFTR modulators (MAYFLOWERS) study: interim update** 17:00 - 17:15

Jennifer Taylor-Cousar (DENVER, United States)

WS15.02 **Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in People with Cystic Fibrosis and ELX/TEZ/IVA-Responsive, Non-*F508del CFTR* Genotypes** 17:15 - 17:30

Milada Mahic (Boston, United States)

WS15.03 **Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in paediatric patients with cystic fibrosis** 17:30 - 17:45

Ngoc Hoa Truong (Paris, France)

WS15.04 **Exploring novel biomarkers to predict response to Elexacaftor/Tezacaftor/Ivacaftor in children with CF: lessons from the air** 17:45 - 18:00

Emmanuelle Bardin (Paris, France)

WS15.05 **Improvements in structural lung disease in people with CF aged 12** 18:00 - 18:15

and above on Elexacaftor/Tezacaftor/Ivacaftor are sustained for up to two years

Paul McNally (Dublin, Ireland)

WS15.06 **Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI as modulator-sparing strategies to reduce cost** 18:15 - 18:30

Marco Zampoli (Cape Town, South Africa)

Workshop
17:00 - 18:30 R2

WS16 - Deep dive into difficult infections

Tavs Qvist (Copenhagen, Denmark)

WS16.01 **To treat or not to treat - a 13 year experience of Mycobacterium abscessus in a single adult cystic fibrosis centre** 17:00 - 17:15

Heather Green (Manchester, United Kingdom)

WS16.02 **Optimization of the management of infections due to *Mycobacterium abscessus* based on the synergy between ß-lactams and ß-lactamases inhibitors** 17:15 - 17:30

Maria Bitar (Paris, France)

WS16.03 **The MAB_4111c epimerase is crucial for glycopeptidolipid biosynthesis, morphotype and pathogenesis of *Mycobacterium abscessus*** 17:30 - 17:45

Laurent Kremer (Montpellier, France)

WS16.04 **When cystic fibrosis triggers a protective immunity against tuberculosis: Loss of CFTR confers resistance to Mycobacterium marinum infections in cystic fibrosis zebrafish models** 17:45 - 18:00

Audrey Bernut (Montpellier, France)

WS16.05 **Changes in *Aspergillus* parameters and antifungal prescriptions in adults with cystic fibrosis treated by Elexacaftor/Tezacaftor/Ivacaftor** 18:00 - 18:15

Lauralie Flan (Lille, France)

WS16.06 **High negative predictive value of serological assays to rule out NTM infections in Cystic Fibrosis patients** 18:15 - 18:30

Jean-Louis Herrmann (Paris, France)

Workshop
17:00 - 18:30 R3

WS17 - Measuring disease activity in cystic fibrosis lung disease

Dario Prais (Petah Tikva, Israel)

WS17.01 **Assessing pulmonary exacerbations (PEx) in the post-modulator era with Oxygen enhanced (OE-)MRI and Multiple breath washout with Short extension (MBW_{ShX})** 17:00 - 17:15

Christopher Short (London, United Kingdom)

WS17.02 **Regulation of elafin expression in bronchial epithelial cells and sputum of people with CF** 17:15 - 17:30

Jan Christoph Thomassen (Cologne, Germany)

WS17.03 **CFTR expression is enhanced in innate immune cells of subjects under therapy with Kaftrio** 17:30 - 17:45

Gloria Sangiorgi (Rome, Italy)

WS17.04 **SCGB1A1 as a potential biomarker of the response to CFTR modulators in Cystic Fibrosis** 17:45 - 18:00

Sophie Gohy (Brussels, Belgium)

WS17.05	**Significant reduction of systemic inflammatory markers in patients with cystic fibrosis with triple therapy lasts for at least 2 years**	18:00 - 18:15

Teresa Fuchs (London, United Kingdom)

WS17.06	**Two years of Elezacaftor/Tezacaftor/Ivacaftor treatment show only a partial anti-inflammatory effect in patients with Cystic Fibrosis**	18:15 - 18:30

Valentino Bezzerri (Rome, Italy)

Workshop
17:00 - 18:30 R4

WS18 - Complex Psychosocial/Nursing Case studies

WS18.01	**Mummy's lungs are very poorly - supporting a mother with cystic fibrosis to talk to her young daughter**	17:00 - 17:18
WS18.02	**Aiding compliance: the importance of Multidisciplinary Team (MDT) home visits for children with Cystic Fibrosis (CF)**	17:18 - 17:36
WS18.03	**Motherhood, pregnancy, and severe cystic fibrosis (CF) disease: the psychosocial challenges for an MDT**	17:36 - 17:54
WS18.04	**Parents complaints about neuropsychological side effects of Elexacaftor/Tezacaftor/Ivacaftor in two children: it all depends on the patient interview**	17:54 - 18:12
WS18.05	**Exploring feasibility and effectiveness of an intervention supporting brain fog in adults post elexacaftor/tezacaftor/ivacaftor: a case study**	18:12 - 18:30

Workshop
17:00 - 18:30 R5

WS19 - Late Breaking Science

Saturday, 08. June 2024

Symposium
09:00 - 10:30 R1

***S21* - Symposium 21 - Masterclass in clinical CF – great cases**

Peter Barry (Manchester, United Kingdom)
Silvia Gartner (BArcelona, Spain)
Ian Balfour-Lynn (London, United Kingdom)
Lieven Dupont (Leuven, Belgium)
Barry Plant (Cork, Ireland)

Symposium
09:00 - 10:30 R2

***S22* - Symposium 22 - Stopping treatments in the era of CFTR-modulators**

Philippe Reix (Lyon, France)
Anna-Maria Dittrich (Hannover, Germany)

Can we stop muco-active inhaled therapy? 09:00 - 09:22

Gwyneth Davies (London, United Kingdom)

When can we stop inhaled antibiotics? 09:22 - 09:44

Marianne S. Muhlebach (Chapel Hill, United States)

Is physiotherapy still useful when there is no sputum? 09:44 - 10:06

Lisa Morrison (Glasgow, United Kingdom)

Insulin: can it be stopped? 10:06 - 10:30

Laurence Kessler (Strasbourg, France)

Symposium
09:00 - 10:30 R3

***S23* - Symposium 23 - Recent advances in pulmonary function testing techniques and equipment**

Clémence Martin (Paris, France)
Paul McNally (Dublin, Ireland)

What does FEV1 now mean in the modulator era? 09:00 - 09:22

Felix Ratjen (Toronto, Canada)

LCI - not just for kids anymore! 09:22 - 09:44

Christopher Short (London, United Kingdom)

Monitoring lung function at home- what to consider? 09:44 - 10:06

Silke van Koningsbruggen-Rietschel (Cologne, Germany)

Artificial Intelligence and imaging in cystic fibrosis - can we harmonise and democratise the measures and interpretation 10:06 - 10:30

Guillaume Chassagnon (Paris, France)

Symposium
09:00 - 10:30 R4

***S24* - Symposium 24 - Cystic Fibrosis Hepatic Biliary Involvement (CFHBI)**

Isabelle Scheers (Brussels, Belgium)
Emer Fitzpatrick (Dublin, Ireland)

From CFLD to CFHBI: a new classification for hepatobiliary involvement in patients with cystic fibrosis 09:00 - 09:22

Frank Bodewes (Groningen, Netherlands)

The role of liver stiffness measurements for diagnosis, treatment and follow up of CFHBI 09:22 - 09:44

Jérémy Dana (Montréal, Canada)

CFHBI in the adult patient, food for thought for adult hepatology 09:44 - 10:06

Management of advanced liver disease in cystic fibrosis including transplantation 10:06 - 10:30

Marco Cipolli (Verona, Italy)

Symposium
09:00 - 10:30 R5

***S25* - Symposium 25 - Widening the lens - Enriching registry data to focus on the determinants of health**

Domenique Zomer-van Ommen (Baarn, Netherlands)
Daniel Peckham (Leeds, United Kingdom)

Cystic fibrosis-registries to enrich the quality of prospective multi-center observational studies 09:00 - 09:22

Christopher Goss (Seattle, United States)

Cancer and cardiovascular outcomes in people with cystic fibrosis 09:22 - 09:44

Isabelle Durieu (Lyon, France)

Social and environmental determinants of health: comparisons across the globe 09:44 - 10:06

Daniela K. Schlüter (Liverpool, United Kingdom)

Outcomes in those ineligble for CFTR modulators: Who are they, where are they and how are they doing? 10:06 - 10:30

Eitan Kerem (Jerusalem, Israel)

Closing Plenary
11:00 - 12:30 R1

Closing Plenary

Perspective of CF in under-resourced regions 11:00 - 11:30

Marco Zampoli (Cape Town, South Africa)

CFTR and carcinogenesis: a scientist’s perspective 11:30 - 11:45

Margarida Amaral (Lisboa, Portugal)

CFTR and carcinogenesis: a clinician’s perspective 11:45 - 12:00

Daniel Peckham (Leeds, United Kingdom)

ECFS President Address 12:00 - 12:30

Jane Davies (London, United Kingdom)